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Resumo 
 O Papilomavirus Humano (HPV) consiste em pequenos fragmentos circulares de 
ADN de dupla cadeia sem invólucro, associado ao desenvolvimento de lesões benignas e 
malignas na pele e mucosas queratinizadas. O murganho transgénico K14-HPV16 é um 
modelo útil para estudar o processo de carcinogénese induzido por HPV, dado que se 
assemelha ao processo que acontece em doentes oncológicos. Este processo é 
acompanhado por um complexo infiltrado de leucócitos que desempenham um papel 
decisivo quer na progressão quer na regressão das lesões. Os linfócitos T CD8+ 
citotóxicos (CTL) são uma parte importante deste infiltrado dado que são capazes de 
destruir células infectadas por vírus e células tumorais. Neste trabalho, a infiltração e 
actividade dos CTL foi analisada em diferentes tempos de vida e diferentes lesões. Ainda, 
foi analisado o efeito de dois imuno-moduladores – uma toxina imunosupressora 
(ptaquilosídeo – PTQ) e um fármaco anti-inflamatório (celecoxib – CXB, um inibidor 
selectivo da ciclooxigenase-2) – na infiltração das células T CD8+ e na sua actividade. 
Após o sacrifício dos murganhos, foram colhidas amostras de pele do peito de 
murganhos wild-type (WT, HPV-/-) e transgénicos (HPV+/-), que foram tratados com PTQ, 
com CXB ou não receberam tratamento. Os fragmentos de pele foram digeridos com 
colagenase e a suspensão celular obtida foi analisada por citometria de fluxo. Para além 
disso, foram colhidas amostras de pele correspondentes para análise histológica. 
 Todos os murganhos HPV-/- apresentam histologia da pele normal enquanto todos 
os animais HPV+/- exibem lesões cuja agressividade aumenta através de etapas etárias 
consecutivas. Verificou-se que os murganhos transgénicos apresentam maior infiltração e 
actividade de células T CD8+ quando comparados com animais WT da mesma idade e, 
que a activação destas células aumenta com a idade e acompanha a progressão das 
lesões. Foram também estudados os efeitos de uma toxina de origem vegetal, o 
ptaquilosídeo, que se pensa contribuir para a carcinogénese induzida por papilomavírus 
em animais e em populações humanas. Os murganhos transgénicos tratados com PTQ 
mostram menor percentagem de linfócitos T CD8+ activados quando comparados com os 
animais HPV+/- não tratados, revelando um novo efeito imunossupressor desta toxina. Por 
outro lado, os murganhos transgénicos tratados com CXB apresentam menor infiltração 
de células citotóxicas comparativamente com os animais não tratados, mas apresentam 
um aumento da percentagem de linfócitos T CD8+ activados. Esta observação sugere 
possíveis abordagens terapêuticas às neoplasias induzidas pelo HPV, nomeadamente o 
uso de inibidores selectivos da ciclooxigenase-2 para potenciar a actividade dos CTL. 
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 Globalmente, este trabalho levanta diversas questões sobre a função das células 
T CD8+ nos cancros induzidos por HPV, abrindo o caminho para futuros estudos na área 
da imunotoxicologia e da imunoterapia. 
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Abstract 
 Human papillomavirus (HPV) is a small non-enveloped double-stranded circular 
DNA virus associated with the development of cutaneous and mucosal malignancies. The 
K14-HPV16 transgenic mouse is an useful model to study the process of carcinogenesis 
induced by a HPV infection as it closely mimics the occurring process in human patients. 
This process is accompanied by a complex immune cell infiltrate which plays a key role in 
either lesion progression or regression. Cytotoxic CD8+ T lymphocytes (CTL) are an 
important part of this infiltrate as they target virus-infected and tumour cells for 
destruction. Thus, in this work, CTL infiltration and activity was assessed and compared at 
different time-points. In addition, the effect of two distinct immunomodulators – an 
immunosuppressive toxin (ptaquiloside – PTQ) and an anti-inflammatory drug (celecoxib – 
CXB, a selective inhibitor of cyclooxygenase-2) – over CD8+ T cell infiltration and activity 
was examined. 
 Following the mice sacrifice, chest skin samples were collected from untreated, 
PTQ-treated or CXB-treated wild-type (WT, HPV-/-) and transgenic (HPV+/-) mice. Skin 
fragments were digested with collagenase and the obtained cell suspension was analysed 
by flow cytometry. Additionally, matched skin samples were histologically examined. 
 All HPV-/- mice show normal skin histology whilst all HPV+/- animals present skin 
lesions, with increased aggressiveness in older and PTQ-treated mice. Untreated 
transgenic mice show increased CTL infiltration and activity when compared to untreated 
WT animals. CD8+ T cell activation is higher in older HPV+/- mice than in younger 
transgenic mice. Moreover, transgenic mice receiving PTQ treatment show reduced 
percentage of activated CTL when comparing with untreated HPV+/- animals. Furthermore, 
CXB-treated mice presented lower infiltration of cytotoxic cells when compared with the 
respective controls. Despite the reduction regarding infiltrating cells, CXB-treated HPV+/- 
mice showed increased percentage of activated CD8+ T lymphocytes than controls. 
 These findings suggest that CTL infiltrate HPV-induced lesions and their activity is 
enhanced in more aggressive lesions. Moreover, the trafficking and activity of these cells 
can be modified when exposed to immunomodulators. In this regard, ptaquiloside seems 
to decrease CTL activity while celecoxib appears to enhance this activity. 
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Human papillomavirus (HPV) is the pathogen responsible for the most common 
sexually transmitted infection among both men and women in the United States [1]. Most 
sexually active people will be infected by HPV during their life. The vast majority of HPV 
infections in immunocompetent individuals are cleared by the immune system, but in 
approximately 10% of cases [2, 3] the persistence of this infection will cause the 
development of disease and progression to cancer. HPV has tropism for skin and mucosal 
epithelia especially from the anogenital and oropharyngeal areas. High-risk HPVs (mostly 
types 16, 18, 31 and 33) act as crucial etiologic agents in cervical carcinoma [4] – which is 
the sixth most frequent malignancy in women worldwide [5] – and are the cause of some 
head and neck neoplasms where incidence depends on the country and other associated 
risk factors like tobacco [6, 7]. 
 Since 1863 [8], when Virchow first hypothesised a link between inflammation and 
cancer, many studies have been carried out in order to understand the underlying 
mechanisms of this relation and its intervenients. The importance of this relation was 
further reinforced by the award of the Nobel Prize to Robin Warren and Barry Marshall for 
their work in discovering Helicobacter pylori as the etiologic agent of inflammation-
associated gastric cancer [9]. The tumour microenvironment is characterised by the 
presence of a variety of leucocytes which have been shown to be attracted by 
chemokines produced by tumour and stromal cells [10]. Lymphocytes are an important 
part of inflammatory infiltrates in the tumour microenvironment [8, 11] and different 
lymphocytic populations can play different roles. For instance, T helper (Th) 1, Tγδ and 
cytotoxic T cells are associated with disease-free survival. In contrary, Th2, Th17 and T 
regulatory (Treg) cells are allied with a poorer outcome [12]. Neutrophils, tumour-
associated macrophages (TAMs), dendritic cells (DCs) and mast cells represent other 
leucocyte populations also frequently found in the tumour environment that may play dual 
roles during carcinogenesis [8, 13]. These tumour-associated inflammatory cells, together 
with the tumour cells, produce and secrete a wide set of cytokines (e.g.: tumour necrosis 
factor (TNF)-α, interleukin (IL)-1, IL-6 and monocyte colony-stimulating factor) and 
chemokines (e.g.: monocyte chemotactic protein-1) that may either help tumour 
progression or contain it [14-17]. 
 In the case of HPV-associated carcinogenesis, the virus infects keratinocytes and 
an immunological response arises as cytokines (mostly TNF-α, IL-1 and type I and II 
interferons – IFNs) are released by the infected keratinocytes and local immune cells [18]. 
However, HPVs may avoid the effector functions of pro-inflammatory cytokines by 
different mechanisms [19-22]. Thus, if the infection persists, the chance of neoplastic 
transformation rises [23]. Besides its importance in the early stages of carcinogenesis, 
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innate and adaptive immune responses are critical factors involved in malignant 
progression. 
 
The Basis of HPV Infection and Cell Transformation 
 Human papillomaviruses have their genome divided in three main regions: the 
non-coding upper regulatory region, the early region encoding six known oncoproteins 
and the late region, which encodes the capsid proteins. The oncoproteins encoded in the 
early region, mainly E6 and E7 but also E5, are key participants in the infectious cycle and 
are the source of the genetic alterations which potentially lead to HPV-associated 
carcinogenesis as reviewed elsewhere [24]. The E5 oncogene is believed to have low 
impact in the maintenance of the malignant phenotype of cervical cancer cells as it 
appears to be deleted in various carcinomas [25]. Nevertheless, when present, it takes an 
important part in multiple mechanisms favouring neoplastic transformation. Some in vitro 
studies have shown that the HPV16 E5 oncoprotein can promote cell cycle progression 
and DNA synthesis by down-regulating the expression of tumour suppressor proteins p21 
and p27 [26, 27]. Moreover, this oncoprotein is central to evasion of the host 
immunosurveillance. In E5-expressing cell lines antigen-presenting major 
histocompatibility complex (MHC) class I molecules appear to be trapped in the Golgi 
apparatus which reduced their surface expression [28, 29]. The down-regulation of MHC 
class I on cells expressing E5 ultimately impairs their recognition and clearance by 
cytotoxic T lymphocytes (CTL). The early genes E6 and E7 are known to have great 
oncogenic potential. They play a pivotal role in HPV-mediated carcinogenesis as they 
react with important tumour suppressor proteins impairing their functions. Thus, E6 binds 
to and promotes the degradation of the p53 tumour suppressor protein [30, 31], impairing 
important mechanisms of defence such as DNA repair and apoptosis. Additionally, the E6 
protein facilitates carcinogenesis by reducing cellular senescence (as a result of 
telomerase activation [32]), activating the NF-κB pathway and evading the interferon 
response [24]. The E7 oncoprotein binds to tumour suppressor proteins of the 
retinoblastoma family of proteins (pRb) and induces their inactivation [33, 34], therefore 
increasing DNA synthesis and boosting cellular proliferation. Furthermore, E7 is able to 
promote genomic instability, which increases the likelihood of malignant progression [24]. 
Together, the E6 and E7 oncogenes are capable of transforming and induce the 
immortalization of keratinocytes [35]. Until today, the three early proteins mentioned 
above appear to be, of all HPV proteins, the ones with higher oncogenic potential. Given 
their roles in evading host immunity, it is important to understand how the human immune 
system responds to HPV infection. 
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HPV Infection vs. Host Immune Response 
 Along the years, mammals have grown complex innate and adaptive immune 
mechanisms to control autoimmunity and to protect the host against microbial infections. 
Viruses can be detected by cellular receptors generally designated as pattern recognition 
receptors (PRRs), which trigger innate immune mechanisms that subsequently may be 
followed by a more specific adaptive immune response. These cellular receptors are 
proficient at recognising several pathogen-associated molecular patterns, like viral DNA or 
RNA or bacterial cell wall or intracellular components, and also interacting with danger-
associated molecular patterns like intracellular molecules released from damaged cells 
and cells undergoing unprogrammed cell death [36]. HPVs are double-stranded DNA 
viruses that are most likely to be recognized by Toll-like receptor 9 (TLR-9). This receptor 
is intracellularly expressed in the membrane of endolysosomes and recognizes 
unmethylated CpG-DNA sequences harboured by pathogens like viruses, bacteria and 
protozoa [36]. However, HPVs appear to somehow surpass these PRRs. The 
oncoproteins E6 and E7 may promote the down-regulation of TLR-9 as has been shown 
in vitro for HPV16 [37]. Therefore, at the start, the HPV infection seems to occur without 
the awareness of the host immune system [38]. Furthermore, in case of a persistent 
infection, the virus impairs immune cell functions as well as several molecular pathways 
involved in the immune response [39]. Also, other innate immune mechanisms, like the 
IFN response, can be abrogated by the actions of some HPV oncoproteins, as mentioned 
above. 
 HPV is transmitted through skin-to-skin contact, usually through micro wounds. 
There exists a variety of immune cells divided between the dermis and epidermis. In the 
epidermis, the main cellular population are keratinocytes but there can also be found 
Langerhans cells and T lymphocytes [39]. Keratinocytes, the main targets of HPV, are 
capable of some immune functions. These cells can produce and release cytokines, 
induce the activation of memory T cells and may also act as non-professional antigen-
presenting cells (APCs) [40]. Hence, keratinocytes are of great importance in the initiation 
of an immune response against HPV infections. On the other hand, the majority of the so-
called “classical” immune cells (macrophages, DCs, T lymphocytes and others) can be 
found in the dermis [39]. Both keratinocytes and immune cells on site are capable of pro-
inflammatory cytokine production [41] and antigen presentation in response to several 
pathogens. Although the innate immune response to HPV infections remains poorly 
understood, the immunological processes described above are thought to be the main 
ones responsible for the initiation of an adaptive immune response, which will determine 
the clearance or persistence of the infection. In fact, only about 10% of HPV infections will 
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develop clinical symptoms and possibly evolve to cancer [2, 3]. Therefore, warts and low 
grade cervical intraepithelial neoplasms (CIN1) are in most cases forced to regress by the 
cell-mediated adaptive immune response [42]. It has been shown that CD4+ and CD8+ 
HPV16-specific T cells migrate to the skin after intradermal challenge with HPV16 
peptides [43]. This cellular migration event appears to be followed by an antibody-
mediated response, as observed in HPV-infected women [44]. Still, antibody titres are low 
and many women may even not produce them. 
 
HPV-associated Chronic Inflammation 
 The above described mechanisms are thought to explain how a human immune 
system reacts since the beginning of a HPV infection until the moment of immunological 
clearance. However, as seen earlier, HPV oncoproteins have ways of evading the host 
immune response. This evasion favours the persistence of the infection, which in turn may 
promote tumourigenesis. 
 In this context, the cellular content of the inflammatory infiltrate is decisive for 
either neoplastic transformation or elimination of infected/transformed cells (Fig. 1). While 
some cellular populations support HPV’s immune evasion and cell transformation 
mechanisms, others have a role in inhibiting malignant progression or even in potentiating 
tumour regression. For instance, T regulatory (Treg) cells facilitate the viral immune 
evasion. These cells display the CD4+CD25+FoxP3+ phenotype and play an 
immunosuppressive role important to prevent self-aggression by the immune system [45]. 
Because of their immunosuppressive function, Treg cells are often associated to 
persistent infection and tumour progression. Indeed, studies have shown a correlation 
between increased frequencies of FoxP3+ T cells at both systemic [46] and cervical [47] 
level and HPV persistent infection. Furthermore, a study has shown the chemokine 
CXCL12 (which is not expressed in normal skin) to act as a chemoattractant for Treg cells 
[48]. This work shows evidence that HPV stimulates an increased production of CXCL12 
which draws a rising number of FoxP3+ cells. Besides Treg cells, another subset of CD4+ 
T cells can have pro-tumour functions. Type-2 helper T (Th2) cells can also contribute to 
impair the protective immune response, predominantly of the Th1 type, in the tumour 
microenvironment as they produce IL-4, -5 and -13, as well as IL-10. As seen earlier, this 
type of immune response facilitates malignant progression [12]. Furthermore, 
macrophages are thought to be a major component of tumour infiltrates [8] and are highly 
frequent in HPV-associated tumours [49]. In the presence of Th2-type cytokines like IL-4 
and IL-13, tumour-associated macrophages (TAMs) are alternatively activated and 
acquire the M2-phenotype [50]. Unlike the M1 macrophages, these M2 cells express 
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various features and functions that are commonly associated with immune regulation and 
tumour progression. For instance, M2 TAMs, together with mast cells, are an important 
source of growth factors (e.g.: vascular endothelial growth factor – VEGF), cytokines (e.g.: 
TNF-α, transforming growth factor-β), proteases (e.g.: matrix metalloproteinases) and 
other molecules which in turn promote angiogenesis and tissue remodelling [51, 52]. 
These events facilitate the intake of nutrients and provide other stimuli which help tumour 
growth, invasion and metastasis. On the other hand, TAMs can be classically activated 
upon microbial stimuli or induced by pro-inflammatory cytokines, such as IFN-γ, to play 
important anti-tumour functions [50]. M1-type TAMs can, therefore, act as inducer and 
effector cells in Th1-type immune responses against tumours. They usually display an IL-
12high, IL-23high phenotype and produce high levels of pro-inflammatory cytokines (IL-1β, 
IL-6 and TNF-α) and reactive nitrogen species [53]. Besides M1 TAMs, other cellular 
populations play important anti-tumour roles among the largely heterogeneous tumour 
inflammatory infiltrates. T lymphocytes are also important immune effectors. Type-1 
responses, mediated by Th1 cells represent the prototypic response adequate to 
eradicate cancer cells. The differentiation of this type of CD4+ T cells is driven by IL-12 
and they are characterised by the production of pro-inflammatory cytokines like IFN-γ. Th1 
cancer cells can directly induce the killing of tumour cells through TNF-related apoptosis-
inducing ligand (TRAIL) and/or Fas Ligand (FasL) pathways [54] and can induce the 
cytotoxic activity of CD8+ T lymphocytes and other effector cells through the production of 
specific cytokines [55]. In turn, CD8+ T cells, which may differentiate into cytotoxic T 
lymphocytes (CTL), are commonly protective against intracellular pathogens, like viruses, 
and tumour cells. These lymphocytes were observed in higher frequency in HPV-positive 
carcinomas when compared with HPV-negative lesions [56]. Further, this difference 
correlates with the patients’ prognosis as a higher CD8+ T cell frequency is associated 
with augmented overall survival. Moreover, “natural killer” (NK) cells and NKT cells act 
similarly to CTL but are part of the innate immune response. Unlike CTL, NK cells do not 
require the presence of MHC I molecules on target cells to exert their cytotoxic function. 
Thus, if HPV successfully down-regulates MHC I expression, thereby avoiding the action 
of CTL, infected cells may still be targeted by NK cells. Like CTL, NK and NKT cells 
express IFN-γ, perforin and granzyme and are thus capable effectors in the anti-viral 
immune response [39] as well as being able to also participate in the killing of cancer cells 
[57]. Additionally, several APCs (like DCs and Langerhans cells) are of great value and 
are frequent in the tumour microenvironment. They are essential for the activation of 
effector cells through antigen presentation and cytokine production [13]. 
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Fig. 1: Schematic representation of the immune cell infiltrate in HPV-induced carcinogenesis.  From top to bottom, HPV 
infection induces neoplastic transformation with associated tissue remodelling events which lead to host immune response. 
This response could either contribute to disease progression or regression which is reflected in the cellular populations 
recruited in either case. CD8+, Th1-type CD4+ T, NK cells and M1 macrophages are commonly associated with tumour 
regression while, Treg, Th2-type CD4+ T cells and M2 macrophages are usually related to malignant progression. 
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The cross-talk of immune cells with HPV-infected cells is still not fully understood. 
However, it is generally agreed that the inflammation associated with the viral infection 
facilitates the development of HPV-associated cancers. In general terms, regulatory T 
cells, M2 TAMs, mast cells and Th2 cells most likely represent the immune cells with the 
greatest contribution to persistent infections and malignant progression. Additionally, 
HPV-transformed keratinocytes were shown to produce the immunosuppressive cytokine 
IL-10 in HPV-associated cervical cancer [58], which may be triggered by the virus 
oncoproteins as an immune evasion mechanism. On the other hand, M1 macrophages, 
NK and NKT cells, CTL and Th1 cells are, with the support of APCs, the major 
participants in anti-viral responses and tumour regression. Still, it is important to 
emphasize that this whole interaction in the tumour milieu is greatly complex due to the 
heterogeneity of cellular populations therein, which likely justifies the difficulty in 
characterising the relationship between inflammatory cells and HPV infection. 
 
HPV-induced Carcinogenesis: The Best Models to Understand It 
Along the years, scientists have been improving our understanding of chronic HPV 
infection and its association with carcinogenesis. In vitro and in vivo animal models are 
key elements towards the evolution of scientific knowledge (Table 1) and the in vitro ones 
are already widely used in HPV-induced carcinogenesis research. HPV-related in vitro 
studies include, in most cases, the use of single-layer cultures of common cervical 
carcinoma cell lines (HeLa, SiHa, CaSki and others). In the last two decades, a more 
sophisticated type of in vitro assay was developed and used as an alternative model. 
Organotypic (or raft) cultures allow the proliferation and differentiation of epithelial cells at 
an air-liquid interface on a dermal-equivalent support [59-61]. Thus, these raft cultures are 
useful to study the events occurring in human stratified epithelia in the course of HPV 
infection and HPV-induced carcinogenesis. 
Alongside with the cell culture technique, in vivo animal models are extensively 
exploited for scientific purposes. On one hand, bovine cattle, dogs and rabbits can be 
used to study bovine, canine oral and cottontail rabbit papillomaviruses, respectively [62, 
63]. The study of these animal papillomaviruses is important as they are etiologic agents 
of diseases in farm and companion animals, provide in vivo models for HPV research and 
help to discover new subjects to study on HPV. However, these large animals are not 
common objects of study because they are associated with a great deal of financial costs 
and ethical issues. In turn, the mouse is the most commonly used test subject in health-
associated studies. Mice display a great similarity to humans in terms of anatomy, 
physiology, including the immune one, and genetics which, in addition to its cost-
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effectiveness and a wide set of other advantages, make it applicable for the study of 
human diseases [64]. In the past couple of decades, new HPV transgenic mouse models 
have been created to more accurately infer on the function of some virus’ oncogenic 
proteins. The first transgenic mice were reported in 1993 and incorporated the E6 and E7 
open reading frames (ORFs) in their genome [65]. In this study, the authors targeted the 
oncogene expression to the ocular lens (through the αA crystallin promoter) and showed 
that these genes potentiate cell proliferation and impair cell differentiation. At the same 
time, another study reported the development of neuroepithelial tumours in HPV16 E6/E7 
transgenic mice that employed the human β-actin promoter to target the expression of 
oncogenes [66]. However, these models failed to adequately target the expression of HPV 
oncogenes to relevant tissues and were unsuitable for the study of HPV-associated 
cancers occurring in patients. Besides these, other in vivo animal models were created 
and ameliorated. Thus, mice expressing the early proteins E5, E6 or E7 alone were 
created under the control of the keratin-14 (K14) promoter, targeting gene expression to 
keratinocytes [67-69]. The targeting of HPV DNA to keratinocytes allows a great similarity 
with the multistep process of HPV-associated carcinogenesis that occurs in the clinical 
disease in patients. These models allow a better understanding of these proteins’ 
functions in vivo, which are expected to be similar to their roles in humans. For instance, 
E5 transgenic mice treated with estrogen showed that this gene is capable of inducing 
cervical cancer alone and, when E6 and E7 are present, these act synergically with E5 to 
induce more severe lesions [70]. Additionally, E5 collaborated with the E7 oncogene to 
increase the number and size of tumours. This alerts to the importance of the E5 
oncogene, which may have a finer role in human cancers than is usually assumed and, 
therefore, requires further investigation. In vivo animal models have also been playing a 
part in the study of other HPV-associated malignancies like head and neck [71] or anal 
[72] neoplasia. With the aid of K14-E6 and -E7 transgenic mice, it has been shown that E7 
is the prevailing oncogene in promoting the development of 4-NQO-initiated head and 
neck squamous cell carcinoma (HNSCC) [71]. In addition, K14-E6E7 double-transgenic 
mice developed more and larger tumours and with superior histopathological severity than 
K14-E7 single-transgenic mice. This result highlights the role of E6 which acts in synergy 
with E7 to develop HNSCC.   
The K14-HPV16 is another transgenic mouse model that has been explored in the 
study of inflammation-driven carcinogenesis associated with HPV infection. These mice 
incorporate in their genome the entire early region of the human papillomavirus type 
16DNA and the expression of these HPV genes is also targeted to basal keratinocytes. 
This model is more adequate to study the events of carcinogenesis because it comprises 
all the virus oncogenes that control the early stages of the disease whilst the previously 
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described models target oncogene expression to uncharacteristic locations or are 
transgenic for only certain oncogenes, thus helping to study the role played by the 
respective protein. The K14-HPV16 mouse model was created by Arbeit et al. in 1994 [73] 
and further characterized in 1996 [74]. A landmark study demonstrated that chronic 
estrogen exposure induces the malignant transformation of squamous epithelium of the 
cervix and vagina in transgenic mice [75]. In fact, a cross-species comparison study 
showed great similarity in the features of carcinogenesis between human cervical disease 
and K14-HPV16 transgenic mice [76]. Both patients and transgenic mice present 
histological stages characteristic of squamous carcinogenesis marked by an increase of 
VEGF expression and an up-regulation of inflammation and angiogenesis during 
squamous carcinogenesis stages. This evidence strengthens the pertinence of this animal 
model to study the multistage process of carcinogenesis and the roles of innate and 
adaptive immunity. Recently, immunocompromised mice receiving tumour xenografts 
have been used as a model to study novel therapeutics, new molecular targets and to 
understand the biologic mechanisms of treatment sensitivity and/or resistance [77, 78]. 
However, these mice do not have a functional immune system and thus cannot mount an 
effective immune response against the tumour. In these mice, the tumour growth is 
heterotopic, instead of orthotopic, due to its atypical location. Additionally, in this model, 
the lesions do not develop through a multi-step process like the ones occurring in HPV-
induced carcinogenesis but appear with a malignant phenotype at time of transplantation. 
Therefore, immunocompromised mice xenografts do not seem reliable to be used in the 
proposed HPV-associated studies as they do not mimic the carcinogenesis process 
occurring in clinical disease. The K14-HPV16 transgenic mouse model should be a fitting 
alternative to gain knowledge of these matters. 
 
Table 1: In vitro and in vivo models for HPV research. Abbreviations: CRPV – Cottontail Rabbit Papillomavirus; 
CPV-1 – Canine Oral Papillomavirus; BPV – Bovine Papillomavirus. 
Model Main Characteristics References 
In vitro   
HeLa, SiHa, CaSki Cell lines obtained from cervical cancer patients, 
expressing HPV-18 (HeLa) or HPV-16 (SiHa and CaSki). [79-84] 
 
  
Organotypic 
cultures 
Proliferating keratinocytes cultured in a dermal-equivalent 
support; Allows some degree of histologic interpretation; 
May be used to mimic HPV-induced squamous lesions. 
[60, 61] 
In vivo   
Cottontail Rabbit, 
Dog, Bovine 
Naturally or experimentally infected with CRPV, CPV and 
BPV, respectively; Allows comparative studies with HPV; 
Their use as models is limited by ethical and financial 
edges. 
[62] 
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Mice 
  
αA-HPV16-E6/E7 HPV oncogenes are expressed in the mice ocular lenses; Does not affect the animal viability. [65] 
 
  
hAc-HPV16-E6/E7 Develop neuroepithelial tumours; Is not possible to define a pre-neoplastic phase; Exhibit rapid malignant progression. [66] 
 
  
αHPV18-E6/E7 
HPV-18-E6/E7 oncogenes are targeted to the ocular 
lenses; May be useful to study some factors that play a 
part in carcinogenesis, namely the roles of p53 and pRB 
proteins. 
[85] 
 
  
UC-HPV11-E2 The HPV-11-E2 gene is expressed in several cell types; Useful for the study of the E2 protein. [86] 
 
  
HPV18-URR, 
HPV11-URR 
The upstream regulatory region of HPV type-18 or -11 is 
expressed only in epithelial cells; For both types, HPV is 
active in gland cells which may originate adenocarcinomas. 
[87, 88] 
 
  
NOD-scid-
IL2Rgammanull 
(NSG), Nude-Fox 
n1null 
Immunodeficient mice used for human head and neck 
tumours xenografts; These models skip the carcinogenic 
process; May be useful for testing new therapeutic 
strategies. 
[77, 78] 
 
  
K14-HPV16-
E5/E6/E7 
HPV-16 oncogenes are expressed only in keratinocytes, 
mimicking the site of clinical disease; These single-
transgenic mice are useful to study the role of the 
respective oncoprotein in HPV-induced carcinogenesis. 
[67-69] 
 
  
K14-HPV18-E7, 
K14-HPV8-E2 
Allow the study of the function of each oncogenic protein 
from the respective type of HPV.  [89, 90] 
 
  
K14-HPV8 
The HPV-8 early genes are targeted to be expressed in 
basal keratinocytes; Is appropriate to the study of HPV8-
induced carcinogenesis. 
[91] 
 
  
K14-HPV16 
The HPV-16 early genes are expressed in basal 
keratinocytes; Is very useful to reproduce the multi-stage 
carcinogenic process occurring in human disease; Shares 
histological features with human lesions; Shares patterns 
of angiogenesis with human cervical carcinogenesis. 
[73, 74, 76] 
 
K14-HPV16 Transgenic Mice as a Model for Inflammation-
associated Carcinogenesis 
In K14-HPV16 transgenic mice, inflammation rises at the sites where HPV is 
expressed and progresses along the time while playing a part in carcinogenesis. For that 
reason, this in vivo animal model is suitable for studying the features involved in 
inflammation-associated carcinogenesis. As so, this model is also adequate to study the 
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effect of anti-inflammatory drugs as possible therapeutic agents to treat inflammation and 
its associated malignancies. 
The K14-HPV16 mouse model helped to understand that CD4+ T lymphocytes 
may promote the development of dysplasia in the skin instead of having an immune 
surveillance function [92]. Mice with a genetic deletion of CD4+ T cells presented a 
reduced incidence of carcinomas when compared with controls. These results are in 
agreement with the events occurring in human patients, where women with cervical 
intraepithelial neoplasia (CIN) 3 lesions had a higher frequency of CD4+CD25hi Treg cells 
when compared to patients with CIN0 and CIN1/2 [46]. However, not only CD4+ T cells 
may contribute to increased incidence of carcinomas. The absence of B lymphocytes 
impairs the ability of innate immune cells to infiltrate and become activated in neoplastic 
skin [93]. B cells do not infiltrate the tumour site but they secrete immunoglobulins (Ig) 
which are deposited in the neoplastic tissue. The reduction in infiltrating innate immune 
cells in premalignant skin results in deficient angiogenesis and diminished keratinocytes 
hyperproliferative activity. Therefore, carcinogenesis promoted by chronic inflammation 
requires the presence of B cells. In addition, also mast cells (MCs) may be important in 
malignant progression. The absence of these cells seems to compromise the initial 
features of malignant progression in vivo, while its presence is usually associated with 
increased angiogenesis [94], therefore suggesting a pro-tumour role of MCs during cancer 
progression. Mast cells, among other immune and stromal cells, are an important source 
of the matrix metalloproteinase 9 (MMP9) which seems to play a pro-tumour role as it 
increases the incidence of carcinomas in HPV-transgenic mice [95]. However, in the 
presence of MMP9 the arising tumours are less aggressive than in its absence. MMP9 
appears to act as an important mediator of angiogenesis and regulator of epithelial 
proliferation and therefore permits the faster tumour progression when compared to 
MMP9-deficient mice [96]. Paradoxically, tissue inhibitors of metalloproteinases (TIMPs), 
namely TIMP-1, which should oppose the action of MMPs, also appear to enhance 
epithelial carcinogenesis [97]. It is reported that the expression of TIMP-1 increases 
during the course of malignant progression in vivo promoting carcinogenesis. This 
promotion is most likely due to the TIMP-1 capacity to potentiate the proliferation of 
keratinocytes. In addition, also the complement system is activated during multi-step 
carcinogenesis, albeit its component C3 is not responsible for recruiting immune cells to 
the tumour milieu [98]. In fact, extensive regions of IgG deposition were observed in 
hyperplastic and dysplastic skin of HPV16 mice which was comparable to HPV16 mice 
lacking the complement protein C3. This outcome suggests an antibody-mediated 
mechanism, independent of complement activation, to mediate the recruitment of immune 
cells during carcinogenesis. A more recent study suggests that the peripheral activation of 
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an antibody-mediated response promotes the development of squamous cell carcinoma 
(SCC) by local binding of the Fc γ-receptor (FcγR) on resident and recruited immune cells 
[99]. Else, the dominant-negative c-Jun (TAM67) blocks the activation of the transcription 
factors AP-1 (activator protein-1) and NF-κB (nuclear factor-kappa B) which are central in 
the process of tumour promotion and progression [100]. Using HPV16 transgenic mice, it 
has been shown that TAM67 also inhibits the action of the E7 oncogene upon certain 
genes that may enhance carcinogenesis [101]. Additionally, the same study also 
describes that TAM67 down-regulates the expression of the pro-inflammatory enzyme 
cyclooxygenase-2 (COX-2), therefore acting as a tumour suppressor. Furthermore, 
hypoxia is a known feature commonly linked to poor prognosis in most cancers. Hypoxia 
induces changes in cancer tissues which may lead to inhibition of apoptosis, genomic 
instability, angiogenesis, cellular differentiation, invasion, radio-resistance and other 
alterations [102] and so, can be used as a prognostic and therapeutic factor. The hypoxic 
cellular response is coordinated by the hypoxia-inducible factor-1 (HIF-1). This 
transcription factor promotes the expression of vascular endothelial growth factor (VEGF) 
which in turn increases angiogenesis, a known feature related with poor prognosis. In fact, 
in vitro studies showed that HPV oncoproteins E6 and E7 enhance VEGF expression 
through a HIF-1α-dependent mechanism, thus contributing to increased angiogenesis 
[103, 104]. This is in agreement with the observed in K14-HPV16 transgenic mice, where 
HIF-1 is up-regulated during the stages of carcinogenesis [105], suggesting that HIF-1 
promotes local growth and invasion of cervical cancer, similarly to the natural events in 
clinical disease [106]. Furthermore, also integrins play an important role in cancer 
progression and, especially, in metastasis, as they are mediators of cell adhesion [107]. 
Also, the reduced expression of α2β1 integrin resulted in diminished progression from 
papillomatosis to dysplasia and decreased tumour growth [108]. These results suggest 
that the α2β1 integrin is important in regulating and promoting the initial steps of 
carcinogenesis. More, cathepsin L – a lysosomal cysteine endoprotease – can influence 
tumour progression in vivo [109]. When cathepsin L is absent in K14-HPV16 mice these 
have a higher proliferative activity of keratinocytes, faster development of dysplasias and 
increased frequency of metastasis when compared to animals in the presence of this 
endoprotease [110]. Therefore, these data are suggestive of an anti-tumour role for 
cathepsin L during carcinogenesis. In conflict with this conclusion, another study suggests 
that cysteine cathepsins, including cathepsin L, promote tumour progression in vivo [111]. 
This report shows augmented progression from dysplasia to SCC, enhanced cathepsins 
expression, reduced apoptosis, increased cell proliferation and promotion of angiogenesis 
in K14-HPV16 mice with cystatin C deficiency. Cystatin C is the most abundant of all 
cystatins which are endogenous inhibitors of cathepsins. Therefore it seems paradox that 
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both cathepsin L and cystatin C present anti-tumour functions. Else, it has been reported 
that neuropilins – transmembrane receptors for the VEGF family of angiogenic proteins 
and the class 3 semaphorin family of guidance proteins – are over-expressed in samples 
of dysplasia and SCC from K14-HPV16 transgenic mice when compared to controls [112]. 
Nevertheless, neuropilins are only expressed in differentiated tumour cells. More recently, 
the expression levels of the microRNA (miR)-155 were measured in K14-HPV16 
transgenic mice in order to understand the possible influence of HPV with this biomarker 
[113]. In this study, the HPV-positive mice presented significantly lower levels of miR-155 
when compared with HPV-negative controls, suggesting that low levels of miR-155 may 
play a role in early phases of HPV-associated carcinogenesis. The same group of 
researchers also analyzed the expression of miR-21 in ear and chest skin samples of 
HPV16-/- and HPV16+/- mice [114]. Levels of miR-21 expression were higher in less 
aggressive lesions (hyperplasia) when compared with more aggressive ones (carcinoma 
in situ), which is in agreement with the anti-inflammatory properties of miR-21 and 
suggests that higher levels of this molecule may counteract malignant progression. 
 
Modulators of the immune response and their effect over CD8+ T 
cells 
As seen earlier, the process of carcinogenesis induced by HPV infection is closely 
associated with an intricate immune cell infiltrate and its soluble mediators [115]. Some of 
these cell populations are commonly linked with tumour regression, as is the case of M1 
macrophages, Th1 and cytotoxic T lymphocytes [12]. The latter, CTL, are specialists in 
virus-infected and tumour cell destruction and, therefore, represent a key population in 
anti-tumour immunity. These cells become activated when viral or tumour antigens are 
presented in MHC I molecules together with the required co-stimulatory signals [116, 117]. 
Upon activation, CD8+ T cells exert their functions either directly, by releasing cytotoxic 
granules (rich in perforin and granzymes) or cell-cell contact (e.g. FAS-FASL); or 
indirectly, following an IFN-γ-dependent mechanism [118, 119]. In fact, CTL have already 
been shown to infiltrate the tumour microenvironment and promote its regression in 
several malignancies including HPV-associated cancers [56, 120, 121]. 
The occurring immune response can suffer alterations in the presence of 
immunomodulatory stimuli which can be induced, for instance, by toxins or medical drugs. 
Hence, immunomodulators can promote either immunosuppression or immunostimulation 
and, therefore, alter the balance between regulatory and effector cells, resulting in 
improved or impaired immune defensive mechanisms [122]. For instance, ptaquiloside, a 
carcinogenic toxin found in bracken (Pteridium spp.), has some immunomodulatory effects 
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[123]. Bracken toxins are hypothesized to drive the malignant progression of 
papillomavirus-induced upper digestive lesions in cattle and human populations, as 
remarked by Chang et al. [124]. Ptaquiloside is a chemically unstable compound that has 
been shown to induce splenic white pulp atrophy, neutropenia, reduced NK cells activity 
and a B-cell lymphoproliferative malignancy [125-128]. However, until now, there are no 
reports of an association between ptaquiloside and CD8+ T lymphocytes. In turn, 
celecoxib (CXB) is an immunomodulatory drug which specifically inhibits cyclooxygenase-
2 (COX-2). This enzyme plays a key role in the development of an inflammatory response 
[129] and is over-expressed in several types of cancer [130-134]. By selectively inhibiting 
COX-2, celecoxib diminishes the production of prostaglandins without significantly 
impairing the COX-1 isoform [135]. Actually, a few studies have already enlightened the 
effect of this selective COX-2 inhibitor over cytotoxic T cells [136-140]. However, whether 
celecoxib enhances or decreases CD8+ T lymphocytes infiltration and activity varies 
between studies. Still, none of these studies analysed the effect of celecoxib over CTL in 
HPV-associated lesions. 
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Chapter 2: Objectives 
 
The purpose of this work was to assess the infiltration and activity of cytotoxic 
CD8+ T lymphocytes in HPV-induced skin lesions, using the K14-HPV16 mouse model. 
Thus, the work was focused in some more specific aims: 
- To perform a kinetic study of the CTL infiltration and activation by comparing 
lesions from different-aged mice; 
- To analyse the immunomodulatory effect of ptaquiloside over CD8+ T cell 
infiltration and activation; 
- To analyse the immunomodulatory effect of celecoxib over CD8+ T cell infiltration 
and activation. 
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Chapter 3: Kinetics of CD8+ T cells in human 
papillomavirus-induced lesions1 
 
                                                          
1
 The contents of this chapter were adapted from: 
 
- Santos C., Ferreirinha P., Sousa H., Ribeiro J., Bastos M.M.S.M., Faustino-Rocha A.I., 
Oliveira P.A., Medeiros R., Vilanova M., Gil da Costa R.M. (2015) Kinetics of CD8+ T cells in 
human papillomavirus-induced lesions – data from K14-HPV16 transgenic mice. Submitted to the 
journal Tumor Biology with the number TUBI-D-15-04094. 
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Introduction 
Human papillomavirus (HPV) is the main etiologic agent of cervical cancer [4], but 
can also originate anal, skin and head and neck malignancies [6, 141, 142]. Only a 
persistent infection by an oncogenic HPV type (mainly HPV 16 and 18) can induce 
malignant transformation. In approximately 90% of HPV infected individuals the host 
immune system is able to fight the virus and hinder its dissemination. However, in the 
remaining 10%, HPV can effectively evade immune defenses and lead to clinical disease 
[2, 3]. 
K14-HPV16 transgenic mice, created nearly two decades ago [73], are an useful in 
vivo animal model for the study of HPV-induced carcinogenesis. This model shares a 
number of morphologic and molecular similarities to HPV-related human disease [76], 
thus functioning as an excellent replica of the multi-stage process of carcinogenesis. 
Targeting of HPV16 oncogenes to keratinocytes by the keratin-14 (K14) 
promoter/enhancer is the key characteristic of this model [73]. 
HPV-induced carcinogenesis is associated with progressively intense chronic 
inflammation. Therefore, a great diversity of immune cells and a multiplicity of soluble 
mediators can be found within the tumour microenvironment [18]. The inflammatory 
infiltrates provide pro- and anti-tumour stimuli, which will favour either the development or 
the regression of the lesion [55, 143]. 
CD8+ T cells are restricted to major histocompatibility complex class I (MHC I) 
molecules which can present peptides generated from intracellular viruses and/or tumour 
cells [117]. Upon recognizing specific peptides presented on MHC I molecules on the 
surface of professional antigen presenting cells, which also display co-stimulatory 
molecules, these T cells can differentiate into cytotoxic T lymphocytes (CTL), helped by 
cytokine stimuli [116]. CTL are an important part of tumour-specific immunity. They may 
eliminate target cells either directly, through the release of lytic granules containing 
several enzymes (such as perforin and granzyme) or by the engagement of death 
receptors (e.g.: FAS-FASL), and indirectly, following an interferon-γ-dependent 
mechanism which leads to cell cycle inhibition, apoptosis and stimulation of macrophage 
anti-tumour activity [118, 119]. 
Thus, using the K14-HPV16 transgenic mouse model, the aim was to examine the 
kinetics of CD8+ T cell infiltration in HPV-induced lesions during multi-step carcinogenesis 
at different time points. The goal was also pointed to understand whether these cells were 
activated by determining the presence of the lysosome-associated membrane protein 1 
(LAMP1), also known as CD107a, at the cell surface. 
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Material & Methods 
Animals 
Generation of K14-HPV16 mice on a FVB/n background has been previously 
reported [73]. K14-HPV16 transgenic mice were generously donated by Drs. Jeffrey Arbeit 
and Douglas Hanahan (University of California) through the USA National Cancer Institute 
Mouse Repository. The animal experiments were approved by the Universidade de Trás-
os-Montes e Alto Douro ethics committee (10/2013) and the Portuguese Veterinary 
Directorate (0421/000/000/2014). Animals were maintained and bred according to 
Portuguese (Decreto-Lei 113/2013, August 7th) and European (EU Directive 2010/63/EU) 
legislation, under controlled conditions of temperature (23 ± 2 ºC), light-dark cycle (12h 
light/12h dark) and relative humidity (50 ± 10 %), using hardwood bedding. Food and 
water were provided ad libitum. 
 
Mice genotyping  
Animals were genotyped at weaning, using tail tip samples as described previously 
[113, 114]. Briefly, nucleic acids were extracted and DNA quality and purity were 
assessed. HPV16-E6 and -E2 genes were amplified to confirm the presence of HPV DNA 
and mouse β-globin was used as control. Amplicons lengths were confirmed by agarose 
gel electrophoresis. Only hemizygous females were used for the transgenic mouse groups 
in the experiment.  
 
Study Design  
Ten wild-type (WT) (HPV16-/-, Group 1) and twelve transgenic (HPV16+/-, Group 2) 
female mice were euthanized at 24-26 weeks of age. Latter, six HPV16-/- (Group 3) and 
six HPV16+/- (Group 4) female mice were sacrificed when 28-30 weeks-old. The mice were 
humanely sacrificed by intraperitoneal pentobarbital overdose, followed by exsanguination 
through cardiac puncture. Chest skin samples (approximately 4 cm2) were collected for 
cell isolation and flow cytometry analysis. Matched samples were collected for histological 
examination.  
 
Histology  
Skin samples were fixated in 10% neutral buffered formalin for 48h. Samples were 
dehydrated through graded alcohols and xylene and paraffin-embedded in an automatic 
STP 120 processor (Micron, Boise, ID). 2 µm-thick sections were stained with 
haematoxylin-eosin (H&E) for histological examination on light microscopy. Skin samples 
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were classified as normal skin, epidermal hyperplasia or epidermal dysplasia. Minor 
dysplastic foci on a hyperplastic background were also recorded. 
 
Preparation of Single-Cell Suspensions  
Chest skin samples were cleaned from excessive blood vessels and fat tissue and 
cut into small pieces. These fragments were incubated for 2 hours with 125 U/ml type I 
collagenase (Gibco, Life Technologies, Paisley, UK) in RPMI-1640 medium 
complemented with 1% glutamine, 1% penicillin-streptomycin-amphotericin B, 1% HEPES 
buffer (all from Sigma, St. Louis, MO) and 10% foetal bovine serum (BioWest, Nuaillé, 
France) at 37 ºC and 150 rpm in a 3031 orbital incubator (GFL, Burgwedel, Germany). 
The resulting cell suspension was then filtered and centrifuged at 300  for 10 min at 4 ºC. 
Cells were then ressuspended in phosphate buffered saline containing 1% bovine serum 
albumin and 20 mM sodium azide followed by extracellular staining.  
 
Immunophenotyping  
Following cell isolation, the surface phenotype of the collected cells was assessed 
by flow cytometry using specific monoclonal antibodies (mAb). To prevent non-specific 
antibody binding, cells were incubated with anti-mouse CD16/CD32 mAb for FcγR 
blocking. This was followed by incubation with anti-CD8 mAb phycoerythrin-cychrome 5-
conjugate (clone 53-6.7, BD Biosciences, San Diego, CA) and anti-CD107a mAb 
phycoerythrin-conjugate (clone eBio1d4b, eBioscience, San Diego, CA). Following 
extracellular staining, the cells were washed, fixed in 2% formaldehyde and washed with 
phosphate buffered saline containing 1% bovine serum albumin and 20 mM sodium azide. 
Antibody-labelled cells were analysed in an EPICS XL flow cytometer using the 
EXPO32ADC software (Beckman Coulter, Miami, FL). The collected data files were 
analysed using the FlowJo software v10.0.7 (FLOWJO, LLC, Ashland, OR).  
 
Statistical Analysis  
Statistical analyses were executed in the GraphPad software (version 6.0, 
GraphPad Software, Inc. La Jolla, CA). Statistical analysis between group pairs was 
performed using the Mann-Whitney test. 
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Results 
 
Transgenic Mice Show Epidermal Hyperplasia and Dysplasia  
Analysis of skin samples showed that the totality of WT mice (groups 1 and 3) 
presented normal skin histology (Fig. 2a) whilst all transgenic mice presented skin lesions. 
In all 12 mice composing group 2 it was possible to observe simple to papillary, diffuse, 
variably severe epidermal hyperplasia and papillomatosis with orthokeratotic 
hyperkeratosis (Fig. 2b). Inflammation was mild, with a few macrophages, lymphocytes 
and mast cells present in the superficial dermis. Also in this group, 2 animals (16.7%) 
presented small epidermal dysplastic foci. In group 4, 3 animals (50.0%) presented diffuse 
epidermal dysplasia (Fig. 2c); other 3 (50.0%) showed multifocal epidermal dysplasia in a 
hyperplastic background. Sub-epidermal angiogenesis and dermal inflammatory infiltrates 
were prominent, showing numerous mixed mononuclear leukocytes and neutrophils. 
 
 
Fig. 2: Histopathological changes induced by HPV16 oncogenes in FVB/n mice, H&E. a – WT animal; Normal skin 
histology, 	 . b – 24-26 week-old HPV16+/- animal; Epidermal hyperplasia extending to the follicular 
infundibulum and isthmus, 	 . c – 28-30 week-old HPV16+/- animal; Epidermal dysplasia, 	 . Note enhanced 
sub-epidermal inflammatory cell infiltration. 
 
Increased CD8+ T lymphocytes numbers and activation in HPV16+/- mice  
In order to assess the presence of CD8+ T cells in HPV-associated lesions, 
lymphoid cells were isolated from chest skin tissue and analysed by flow cytometry (Fig. 
3a). As shown in Fig. 3b, chest skin samples from HPV16+/- mice (groups 2 and 4) 
presented a significantly higher percentage of CD8+ T cells when compared with those of 
WT animals (groups 1 and 3). Although the percentage of skin CD8+ T cells was slightly 
higher in group 4 than in group 2, it did not reach statistical significant difference.  
In order to determine if the CD8+ T cells found in the skin of HPV16+/- mice 
presented evidence of cytotoxic activity, the surface expression of CD107a was 
evaluated. In CD8+ T lymphocytes CD107a reaches the cell surface when lytic granules 
suffer exocytosis, thus exposing its membrane proteins [144]. Therefore, this lysosome-
associated membrane protein is a commonly used surrogate marker of CTL degranulation 
[145]. As shown in Fig. 3c, the percentage of CD107a+CD8+ T cells in chest skin samples 
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of mice from groups 2 and 4 were found significantly higher when compared with 
respective controls of groups 1 and 3. This indicates that in the HPV16+/- mice skin 
infiltrating CTL released cytotoxic granules. Moreover, in group 4 mice, 100% of which 
show multifocal or diffuse dysplasia, a markedly higher percentage of CD8+ T cells 
express CD107a (P  0.001) than in group 2 mice, of which only 16.7% show focal 
dysplastic lesions. This result shows a positive correlation in the proportions of activated 
CD8+ T cells and lesion severity. 
 
 
Fig. 3: Percentage of CD8+ and CD8+CD107a+ T cells within total lymphoid-gated cells obtained from chest skin 
samples from WT and K14-HPV16 transgenic mice. a – Representative analysis of the gating strategy employed. 
Numbers within graphs correspond to the percentage of the gated population. b – Percentages of CD8+ T cells and 
c – percentages of CD8+CD107a+ T cells in gated CD8+ T cells were determined by flow cytometry after skin tissue 
collection and digestion with collagenase. Chest skin samples were collected from 24-26 weeks-old HPV-/- and 
HPV+/- mice (Groups 1 and 2, respectively) and 28-30 weeks-old HPV-/- and HPV+/- mice (Groups 3 and 4, 
respectively). Group 1, n = 10; Group 2, n = 12; Group 3, n = 6; Group 4, n = 6. Each dot represents an individual 
animal. Bars represent the mean value in each group. ** P  0.01; *** P  0.001. 
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Discussion  
HPV is considered to be the cause of virtually all cases of cervical cancer [146], 
therefore playing a central role in carcinogenesis. Despite the continuous progress in the 
understanding of the immune response against HPV and the development of effective 
vaccines, much is still ignored about the cell-mediated response against HPV-induced 
lesions. HPV-mediated carcinogenesis is commonly associated with chronic inflammation 
[18]. Nevertheless, the complex interactions within the inflammatory infiltrate remain not 
fully understood [39]. 
 The K14-HPV16 transgenic mouse model appears as an appropriate in vivo 
animal model to improve the knowledge on HPV-induced carcinogenesis and elicited 
immune response. Besides cervical cancers, these mice develop aggressive skin lesions 
with greater incidence in the ear and the chest [74]. As expected, it was possible to detect 
a higher incidence of aggressive lesions (epidermal dysplasia) in older transgenic mice 
than in younger ones, which presented mostly hyperplastic lesions. The development of 
dysplastic lesions was accompanied by a dramatic intensification of sub-epidermal 
inflammation. As this process of carcinogenesis is associated with progressive chronic 
inflammation, this model will allow the study of the intervening immune effectors.  
CD8+ CTL are important players in tumour-specific immunity [147]. When CD8+ 
CTL recognize their targets they release lytic granules containing a variety of enzymes 
(perforin, granzyme and other) which allow the killing of virus-infected and tumour cells 
[118]. During exocytosis, CD107a reaches the cell surface as the membrane of lysosomes 
disrupts, thus helping to determine whether the CD8+ T cells are activated [145]. 
In this work, it was possible to observe that CD8+ T cells heavily infiltrate HPV-
induced chest skin lesions in K14-HPV16 transgenic female mice. This data is in 
agreement with previous studies which described the presence of CD8+ T cells in HPV-
induced cervical and skin lesions in human patients [43, 148]. According to one of these 
studies, the presence of CD8+ T cells in cervical tissue was associated with tumour 
regression [148]. The results presented here suggest a trend towards the increase of 
infiltrating CD8+ T cells in chest skin samples of 28-30 weeks-old mice when compared to 
24-26 week-old animals. Although indicating that CD8+ T lymphocytes migrate in greater 
number towards more severe lesions than to less aggressive ones, these results should 
be further confirmed. Nevertheless, this work’s data clearly show that a significant 
proportion of the infiltrating CTL are activated and degranulate. Whether these cells were 
activated at the lesion site or at regional lymph nodes would be an appealing point to 
address hereafter. CD8+ T lymphocytes isolated from older animals present a high degree 
of activation when compared to that isolated from younger mice. This suggests that more 
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CD8+ T cells become activated in response to a more severe stimulus than when 
confronted with a less aggressive lesion. However, despite the increase in number of 
cytotoxic cells and its enhanced activation, the lesions still tend to progress to a poor 
phenotype with aging. Low tumour infiltration by activated CTL has been associated with 
the limiting efficacy of the immune response in eliminating established tumours [149]. The 
results reported herein indicate that however important, CTL recruitment and 
degranulation into lesion areas do not suffice to prevent progressive carcinogenesis in the 
K14-HPV16 transgenic mice. Many immunoevasive strategies have been identified 
preventing the effectiveness of tumour immunity mediated by CTL [150]. However, as a 
high proportion of skin infiltrating CD8+ T cells showed evidence of degranulation in the 
older K14-HPV16 transgenic mice, it would be worth exploring whether the transgenic 
cells might present an intrinsic resistance to cytotoxic mechanisms dependent on CTL 
degranulation. 
 
Conclusion 
The results presented here clearly show that CD8+ T cells infiltrate HPV-induced 
lesions, but indicate their activation is not enough to stop malignant progression in this 
model. These results also support the use of K14-HPV16 mice as an adequate model to 
study the host immune response associated with HPV-induced lesions and help 
developing immunotherapeutic strategies that could prevent carcinogenesis.  
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Chapter 4: Ptaquiloside inhibits tumour-infiltrating CD8+ 
T cells in HPV-transgenic mice 
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Introduction  
 Papillomavirus cause benign and malignant lesions in many wild and domestic 
animal species, as well as in human populations.  Human papillomavirus (HPV) is the 
source of several diseases, including many anogenital and some upper digestive cancers 
[151]. The growing incidence of HPV-positive oropharyngeal cancer is now of particular 
concern [152]. Several bovine papillomavirus (BPV) types, such as BPV1, BPV2 and 
BPV4 are associated with cutaneous and upper digestive papillomatosis, as well as with 
abortive urinary bladder infections [63]. Interestingly, digestive tract cancers induced by 
HPV and BPV share many common features and, possibly, some environmental co-
factors [124]. 
A persistent infection by an oncogenic viral type is mandatory for malignant 
progression to take place [3]. Viral persistence is determined by a complex interplay 
between the host immune system and the virus ability to evade it. In this context, 
environmental immunosuppressants are likely to play an important role.  
Bracken (Pteridium spp.), is a fern belonging to the Pteridaceae family with a 
worldwide distribution [123]. It is known for its ability to facilitate BPV persistence in 
infected cattle, promoting the malignant transformation of upper digestive papillomas into 
squamous cell carcinomas [153]. Importantly, exposure to bracken and its toxins has also 
been associated with an increased risk of developing upper digestive malignancies in 
human populations (reviewed in [123]). Ptaquiloside, the main bracken toxin, is an 
unstable nor-sesquiterpene glycoside of the illudane family, with important immunotoxic 
properties. It has the ability to induce neutropenia and inactivate natural killer (NK) cells, 
which play an important role in innate immunity, by killing virus-infected and neoplastic 
cells [126, 127]. Therefore, it might be hypothesized that these immunosuppressive 
effects could facilitate viral persistence and the progression of early-stage papillomavirus-
induced lesions.  
Cytotoxic CD8+ T lymphocytes (CTL) are another cell population involved in host 
immunity to virus-infected and neoplastic cells as the main responsible for cytotoxic 
functions in an adaptive immune response. CTL target virus-infected and tumour cells via 
antigen presentation by Major Histocompatibility Complex class I (MHC I) molecules [117], 
in the presence of other co-stimulatory signals [116]. These cells may directly induce the 
killing of target cells, by releasing lytic granules or through death receptor engagement 
(e.g. FAS-FASL) or indirectly, by producing IFN-γ, which leads to multiple anti-tumour 
activities [118, 119]. Several HPV and BPV types (including HPV16 and BPV1 and 4) are 
able to down-regulate MHC I expression through their E5 oncoprotein, as an immune 
evasion strategy [154]. However, recent findings confirm that, even under conditions of 
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low MHC I expression, CD8+ T cells play a decisive role in fighting HPV-induced 
oropharyngeal cancers [155]. 
 In the present work, we hypothesize that ptaquiloside, the bracken toxin, exerts its 
immunosuppressive effect by counteracting the action of CD8+ T cells against 
papillomavirus-induced lesions. This would facilitate viral persistence and the progression 
of early HPV- and BPV-induced lesions, posing major risks for human and animal health. 
In order to test that hypothesis, we employed HPV16-transgenic mice and analysed the 
effect of ptaquiloside on the population of skin infiltrating CD8+ T cells. 
  
Material & Methods 
Mice 
 Construction of K14/HPV16 mice on a FVB/n background has been previously 
reported [73]. These animals develop characteristic multi-stage cutaneous and uterine 
cervical carcinogenesis, and were generously donated by Drs. Jeffrey Arbeit and Douglas 
Hanahan (University of California) through the USA National Cancer Institute Mouse 
Repository. The animal experiments were approved by the Universidade de Trás-os-
Montes e Alto Douro ethics committee (10/2013) and the Portuguese Veterinary 
Directorate (0421/000/000/2014). Animals were maintained and bred according to 
Portuguese (Decreto-Lei 113, August 7th) and European (EU Directive 2010/63/EU) 
legislation, under controlled conditions of temperature (23 ± 2 ºC), light-dark cycle (12h 
light/12h dark) and relative humidity (50 ± 10 %), using hardwood bedding. Food and 
water were provided ad libitum. 
 
Mice genotyping 
Animals were genotyped at weaning, using tail tip samples as described previously 
[113, 114]. Briefly, nucleic acids were extracted and DNA quality and purity were 
assessed. HPV16-E6 and -E2 genes were amplified to confirm the integration of HPV 
DNA into the mouse genome and a fragment of mouse β-globin was also amplified to 
confirm the quality of the extracted DNA. Lengths of the fragments were confirmed by 
agarose gel electrophoresis. Only hemizygous female mice were used for the transgenic 
mice groups in the experiment. 
 
Ptaquiloside isolation 
Ptaquiloside was isolated from bracken as previously described [156] with minor 
modifications. Briefly, 1000 g (dried weight) bracken crosiers were harvested at Arcos de 
Valdevez, Portugal, 41º 49´ 12´´ N, 8º 24´ 11´´ W) and a sample was deposited at the 
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Universidade de Trás-os-Montes e Alto Douro herbarium (reference no. 18248). Bracken 
was blended in distilled water (10 L), stirred at room temperature for 1 hour and the 
extract was adsorbed on 3 L of XAD-2 resin (Supelco, Sigma, St. Louis, MO). The resin 
was eluted with methanol (10 L) and the methanol extract was concentrated, dissolved in 
water (400 ml) and extracted with butanol (5		500 ml). The butanol extract was 
chromatographed on silica gel (Merck, Kenilworth, NJ). Fractions containing ptaquiloside 
were separated twice on octadecyl-sylane silica gel (Fujy-Silysia, Kasugai Aichi, Japan) 
using methanol-water mixtures to obtain pure ptaquiloside. The compound was 
distinguished from other closely-related bracken illudane toxins on the basis of its 
characteristic 1H and 13C nuclear magnetic resonance (NMR) signals [157] using an 
Avance III 400 MHz spectrometer (Brucker, Billerica, MA). Aliquots were prepared for 
each experimental week (7.5 mg), freeze-dried and kept at -20ºC until use.  
 
Study Design 
 Thirty transgenic (HPV16+/-) and 15 wild-type (WT, HPV16-/-) female 18-20 weeks-
old mice, showing diffuse cutaneous crusting and papillomatosis were employed. The 
animals were separated into three experimental groups: group 1 (n = 15, HPV16-/- mice), 
group 2 (n = 15, HPV+/- untreated mice) and group 3 (n = 15, HPV16+/- mice treated orally 
with 0.5 mg ptaquiloside per week, for 10 consecutive weeks). The experimental animals 
were monitored daily for signs of stress or disease. All surviving mice were euthanized at 
28-30 weeks of age by an intraperitoneal pentobarbital overdose, followed by cardiac 
puncture and exsanguination. Chest skin samples (approximately 4 cm2) were collected 
for flow cytometry analysis. Matched samples were collected for histological examination. 
 
Ptaquiloside administration and toxicity 
Each week, a 7.5 mg ptaquiloside aliquot was dissolved in 300 µl ethanol (25 
mg/mL) and the individual 0.5 mg dose (20 µl ethanol) was added to a standard wheat 
cookie (Vieira, Vila Nova de Famalicão, Portugal) fragment weighting ca. 100 mg. Each 
dosed fragment was allowed to dry at room temperature for 10 minutes and individually 
administered to a group 3 animal, in an individual empty cage; the ingestion was visually 
monitored. In order to confirm that ptaquiloside was indeed active at the administered 
dosage, we looked for a lymphoid malignancy [128]. Thus, histological analysis of kidney 
samples was used to confirm neoplastic lymphoid cell infiltration in this organ.  
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Skin histology   
 Skin samples were fixated in 10% neutral buffered formalin. Samples were 
dehydrated through graded alcohols and xylene and, paraffin embedded in an automatic 
STP 120 processor (Micron, Boise, ID). 2 µm-thick sections were stained with 
haematoxylin-eosin (H&E) for histological examination on light microscopy. Skin samples 
were classified as normal skin, epidermal hyperplasia, multifocal epidermal dysplasia in a 
hyperplastic background and diffuse epidermal dysplasia. 
 
Isolation of a Single-Cell Suspension 
 Chest skin samples were cleaned from excessive blood vessels and fat tissue and 
cut into small pieces. This fragments were incubated for 2 hours with 125 U/ml of type I 
collagenase (Gibco, Life Technologies, Paisley, UK) in RPMI-1640 medium 
complemented with 1% glutamine, 1% penicillin-streptomycin-amphotericin B, 1% HEPES 
buffer (all from Sigma) and 10% foetal bovine serum (BioWest, Nuaillé, France) at 37 ºC 
and 150 rpm in a 3031 shaking incubator (GFL, Burgwedel, Germany). The resulting cell 
suspension was then filtered and centrifuged at 300  for 10 min at 4 ºC. Cells were then 
ressuspended in phosphate buffered saline containing 1% bovine serum albumin and 20 
mM sodium azide followed by extracellular staining. 
 
Flow Cytometry Analysis 
Following cell isolation, the cellular immune phenotype was assessed by flow 
cytometry using monoclonal antibodies (mAb). Non-specific antibody binding was 
prevented by incubating cells with anti-mouse CD16/CD32 mAb for FcγR blocking. This 
was followed by incubation with anti-CD8 phycoerythrin-cychrome 5-conjugate (clone 53-
6.7, BD Biosciences, San Diego, CA), anti-CD107a (LAMP1) phycoerythrin-conjugate 
(clone eBio1d4b) and anti-CD44 phycoerythrin-cychrome 7-conjugate (clone IM7) mAb 
(both from eBioscience, San Diego, CA). Following extracellular staining, the cells were 
washed, fixed in 2% formaldehyde and washed with phosphate buffered saline containing 
1% bovine serum albumin and 20 mM sodium azide. Antibody-labelled cells were 
analysed in an EPICS XL flow cytometer using the EXPO32ADC software (Beckman 
Coulter, Miami, FL). The collected data files were analysed using the FlowJo software 
v10.0.7 (FLOWJO, LLC, Ashland, OR). 
 
Statistical Analysis 
Flow cytometry statistical analyses were executed in the GraphPad software 
(version 6.0, GraphPad Software, Inc. La Jolla, CA). In column and dot graphs, each point 
is representative of an individual mouse and bars represent the mean value for the 
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respective group. Analysis between group pairs was performed using the Mann-Whitney 
test. Kaplan-Meier survival analysis coupled with a log rank test was performed using the 
PASW Statistics software (version 18, IBM® SPSS®, Quarry Bay, Hong Kong). 
 
Results 
General findings 
Ptaquiloside was isolated at a 0.01% yield from bracken, as previously reported 
[128]. The compound's structure (Fig. 4a) was confirmed using NMR analysis and no 
other illudane glycoside was detected (Fig. 4b, c). Transgenic animals showed 
characteristic diffuse cutaneous hyperkeratosis and erythema, together with variably 
intense pruritus, while WT mice showed normal skin. All mice in groups 1 and 2 survived 
the 10 weeks experimental period. Ten mice (66.7%) from group 3 succumbed before the 
end of the study (Fig. 4d). Histological analysis of kidney samples showed normal 
histology in WT and untreated HPV+/- animals (Fig. 4e) and, moderate to severe, 
multifocal, perivascular infiltration of lymphoblastic cells, showing highly pleomorphic 
nuclei and up to 3 mitotic figures per high-power field in 100% of ptaquiloside-treated 
animals (group 3) (Fig. 4f). 
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Fig. 4:  Ptaquiloside and its leukaemogenic effect in K14-HPV16 mice. a – ptaquiloside's structural formula. b and 
c – partial 2D NMR-HSQC spectra (obtained in CD3OD) for ptaquiloside. Note the correlations between carbons and 
their corresponding hydrogens in the glucose residue (b). Note in particular the correlations between carbons 12 
and 13 at 5.87 ppm and 10.86 ppm respectively, and their corresponding hydrogens in the cyclopropylidene ring 
(c). d – Kaplan-Meier survival analysis. HPV+/- mice treated with ptaquiloside show significantly reduced survival (P 
 0.001) compared with untreated HPV-/- or HPV+/- animals. e – Untreated HPV+/- animal (group 2), showing normal 
kidney histology; H&E 200 . f – Ptaquiloside-exposed HPV+/- animal (group 3) showing typical ptaquiloside-
associated perivascular infiltration by leukaemic lymphocytes. Note marked nuclear pleomorphism and mitotic 
figures; H&E 200 . 
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Cutaneous lesions 
 The histological analysis showed that all group 1 mice (100.0%) presented normal 
skin histology (Fig. 5a) whilst all transgenic mice (groups 2 and 3) presented skin lesions. 
In group 2, 3 animals (50.0%) presented diffuse epidermal dysplasia (Fig. 5b); other 3 
(50.0%) showed epidermal hyperplasia with multifocal dysplasia. Sub-epidermal 
angiogenesis and dermal inflammatory infiltrates were prominent in dysplastic lesions, 
showing numerous mixed mononuclear leukocytes and neutrophils. In group 3, the totality 
of mice (100.0%) showed diffuse epidermal dysplasia (Fig. 5c).  
 
 
Fig. 5: Histopathological changes induced by HPV16 oncogenes in FVB/n mice, H&E. a – group 1 animal. Normal 
skin histology, 400 . b – group 2 animal. Epidermal hyperplasia extending to the follicular infundibulum, 400 . c – 
group 3 animal. Epidermal dysplasia, 400 . Note loss of keratinocytic polarity and differentiation. 
 
CD8+ T lymphocytes are present in ptaquiloside-treated and untreated 
animals 
 In order to determine the proportions of CD8+ T cells present in chest skin with or 
without HPV-associated lesions, samples were collected and cells isolated, followed by 
flow cytometry analysis (Fig. 6a). As shown in Fig. 6b, group 2 and 3 (HPV+/- and 
ptaquiloside-treated HPV+/-, respectively) mice showed significantly higher percentages of 
CD8+ T cells compared with HPV-/- mice (P  0.05). The percentage of CD8+ T cells in 
chest skin was not significantly different between ptaquiloside-treated and untreated 
HPV16+/- mice (groups 3 and 2, respectively). 
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Fig. 6: Percentage of CD8+ T cells within total lymphoid-gated cells obtained from chest skin samples from WT and 
K14-HPV16 transgenic mice. a – Representative analysis of the gating strategy utilized. The number within the 
graph corresponds to the percentage of the gated population. b – Percentages of CD8+ T cells were determined by 
flow cytometry after skin tissue collection and enzymatic digestion. Chest skin samples were collected from 28-30 
weeks-old HPV-/- (Group 1), HPV+/- mice (Group 2) and ptaquiloside-treated (PTQ) HPV+/- mice (Group 3). Group 1, n = 
5; Group 2, n = 5; Group 3, n = 5. Each dot represents an individual animal. Bars represent the mean value in each 
group. * P  0.05. 
 
Ptaquiloside decreases the number of CD8+CD107a+ T cells in HPV16+/- mice 
 Next, CD8+ T cells found in skin samples were analysed with the objective to 
determine if they were actively degranulating, which indicates ongoing cytotoxic activity. 
For that purpose, flow cytometry analysis was performed to assess the expression of 
surface CD107a in these cells (Fig. 7a). A significantly higher percentage of 
CD8+CD107a+ T lymphocytes was observed in HPV+/- mice as compared with HPV-/- 
animals (P  0.01) (Fig. 7b). Additionally, HPV+/- mice exposed to ptaquiloside also 
presented a higher percentage of CD8+CD107a+ T lymphocytes when compared to WT 
animals, but this was significantly reduced when compared to untreated HPV+/- mice (P  
0.05). 
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Fig. 7: Percentage of CD8+CD107a+ T cells within total CD8+ T cells obtained from chest skin samples from WT and 
K14-HPV16 transgenic mice. a – Representative analysis of the gating strategy utilized. Numbers within graphs 
correspond to the percentage of the gated population. b – Percentages of CD8+CD107a+ T cells in gated CD8+ T 
cells were determined by flow cytometry after skin tissue collection and enzymatic digestion. Chest skin samples 
were collected from 28-30 weeks-old HPV-/- (Group 1), HPV+/- mice (Group 2) and ptaquiloside-treated (PTQ) HPV+/- 
mice (Group 3). Group 1, n = 5; Group 2, n = 5; Group 3, n = 5. Each dot represents an individual animal. Bars 
represent the mean value in each group. *P 	0.05; ** P  0.01. 
 
Reduced number of CD8+CD44+ T cells in ptaquiloside-treated transgenic 
animals 
Having determined that CD8+ T cells presented a cell surface phenotype 
associated with degranulation, expression of CD44, a marker indicating a memory cell 
phenotype [158], was also assessed. As shown in Fig. 8 (a and b), a significantly higher 
percentage of CD8+CD44+ T lymphocytes was found in HPV+/- mice as compared with 
HPV-/- animals (P  0.01). Ptaquiloside-treated HPV+/- mice presented a significantly 
reduced percentage of CD8+CD44+ T lymphocytes compared with untreated HPV+/- mice 
(P  0.05). In fact, group 3 did not show statistically different values to group 1 (P  0.05). 
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Fig. 8: Percentage of CD8+CD44+ T cells within total CD8+ T cells obtained from chest skin samples from WT and 
K14-HPV16 transgenic mice. a – Representative analysis of the gating strategy utilized. Numbers within graphs 
correspond to the percentage of the gated population. b – Percentages of CD8+CD44+ T cells in gated CD8+ T cells 
were determined by flow cytometry after skin tissue collection and enzymatic digestion. Chest skin samples were 
collected from 28-30 weeks-old HPV-/- (Group 1), HPV+/- mice (Group 2) and ptaquiloside-treated (PTQ) HPV+/- mice 
(Group 3). Group 1, n = 5; Group 2, n = 5; Group 3, n = 5. Each dot represents an individual animal. Bars represent 
the mean value in each group. * P  0.05;** P  0.01. 
 
Discussion 
 CD8+ T lymphocytes are important effectors of the cell-mediated immune 
response, especially against virus-infected or tumour cells [117]. Upon activation these 
cells may degranulate, releasing a set of lytic enzymes capable of destroying target cells 
[159]. CD107a is a lysosome-associated membrane protein which can be used as 
surrogate marker of degranulation [145]. In CD8+ T lymphocytes, CD107a reaches the cell 
surface when lytic granules are exocytosed, thus exposing its membrane proteins [144]. 
As CD8+ T cells need to be activated in order to release cytotoxic granules, the presence 
of CD107a at the cell surface is useful to determine their activation status [145].  
Additionally, CD8+ T cells may also acquire a memory phenotype, allowing a quicker recall 
response, as memory T cells can be more easily activated than naive T cells [159]. CD44 
is a cell-surface glycoprotein and is currently considered the best marker to identify 
memory CD8+ T cells [158]. Furthermore, CD44 is thought to act as a regulator of the 
motility of CTL in the tumour microenvironment [160]. 
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Although many papillomavirus (including some oncogenic HPV and BPV types) 
down-regulate MHC I expression as a strategy to evade immune surveillance mediated by 
CTL [154], these cells still play a major role against papillomavirus-induced lesions, 
namely in HPV-induced oropharyngeal cancers [155]. Evading the host immune response 
is critical for maintaining a long-term infection, allowing tumour progression. In this 
context, environmental (e.g. dietary) immunosuppressant products such as bracken and 
its toxin, ptaquiloside, may play an important role.  
In this work, as expected, WT mice had no HPV-associated lesions, whilst age-
matched K14-HPV16 transgenic mice showed hyperplastic lesions with dysplastic foci or 
diffuse dysplasia. It is possible that the diffuse dysplastic lesions observed in ptaquiloside-
treated animals represent a more aggressive stage in multi-step carcinogenesis compared 
with the often focal dysplasia observed in untreated animals. However, the small number 
of animals that survived the experimental period and the absence of obviously invasive 
lesions do not allow us to firmly conclude that ptaquiloside enhanced tumour progression. 
The increasing aggressiveness of dysplastic versus hyperplastic lesions was 
accompanied by an increased bulk of infiltrating immune cells.  
These results indicate that HPV-induced hyperplastic and dysplastic skin lesions in 
K14-HPV16 transgenic mice show increased infiltration of CD8+ T cells when compared to 
normal skin from age-matched WT mice. Ptaquiloside reduced the CD8+ T cell infiltration, 
although only slightly (P > 0.05). Nevertheless, ptaquiloside did induce a significant 
reduction in CD107a+ and CD44+ CD8+ T cells.  
Altogether, these data show that cytotoxic T cells migrate to the site of HPV-
induced lesions, are activated to degranulate and acquire a memory-phenotype and, that 
ptaquiloside is capable of impairing the function of these cells, explicitly by inhibiting 
cellular activation and memory phenotype acquisition. The molecular mechanism behind 
this impairment should be an alluring topic for future research. 
Grazing animals and human populations worldwide are easily exposed to bracken 
and its illudane toxins, including ptaquiloside and other related compounds [123]. Bracken 
is an abundant weed, especially in poorer pastures, and  ptaquiloside accumulates in 
bovine and ovine milk and meat [161-163], besides contaminating underground waters 
[164]. Moreover, some human populations in different countries consume bracken shoots 
(known as croziers, broto de samambaia in Portuguese or warabi in Japanese) as part of 
their daily diet [123]. In China, the production of dry Pteridium aquilinum var. latiusculum 
for food uses (locally known as juecai) was estimated to involve approximately 1000 
companies in a business worth 300 million USD per annum [165]. This is considered the 
most widely-consumed fern in China, with an estimated annual production of 1200 tons in 
the Zhouzhou county, province of Hunan. Bracken and ptaquiloside are well-known 
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carcinogens [128, 166-169] but also show important immunotoxic properties. The present 
ptaquiloside yield is in agreement with other previous studies using samples from the 
same area [128]. Ptaquiloside extreme instability makes its isolation, manipulation and 
administration very challenging, as it easily originates the inactive pterosin B [157]. 
However, the typical toxicities and dramatic mortality rate now induced leave no doubts as 
to its activity. The dosage now employed was similar to the one used intraperitoneally on 
CD-1 mice [128]. However, the transgenic K14-HPV16 mouse strain shows added frailty 
due to its characteristic lesions, and this is likely to explain the higher mortality now 
observed. 
Bracken induces other immunosuppressive effects involving innate immune cells. 
These include neutropenia and the down-regulation of NK cell activity [127]. This second 
effect was recently proposed to contribute to urethane-induced lung carcinogenesis [170]. 
However, due to ptaquiloside scarcity and instability, studies on bracken toxicology 
frequently resort to complex and poorly characterized plant extracts, thereby 
compromising the study's ability to draw significant conclusions. The present study is the 
first to address the immunosuppressive effects of ptaquiloside in a relevant model of 
papillomavirus-induced cancer.    
Over the years, the K14-HPV16 transgenic mouse model emerged as a valuable in 
vivo mock-up for the study of HPV-induced multi-stage carcinogenesis [73, 74]. 
Importantly, the expression of viral genes is targeted to basal keratinocytes, the cellular 
type affected by natural papillomavirus infections. The high histological resemblance 
between the lesions taking place in transgenic mice and the ones occurring in human 
patients support the utility of this animal model [76]. Furthermore, K14-HPV16 mice are 
useful to study the HPV-associated immune response that accompanies carcinogenesis 
[93, 113, 114]. 
The knowledge on the immune response surrounding papillomavirus-induced 
carcinogenesis is in constant growth but the cell-mediated immune response against 
neoplastic and pre-neoplastic lesions remains poorly understood. This lack of knowledge 
may be holding back the development of more effective therapeutic strategies, including 
therapeutic vaccines. 
   
Conclusion 
 The results confirm the role of ptaquiloside as an immunosuppressive toxin, 
capable of enhancing the immune evasion strategies characteristic of papillomavirus-
transformed cells. Ptaquiloside reduces CD8+ T cell infiltration of papillomavirus-induced 
lesions, as well as the effector and memory functions of these cells, as shown by a 
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reduced expression of CD107a and CD44. These findings are of particular concern in the 
context of oropharyngeal high-risk papillomavirus infections, where dietary toxicants like 
ptaquiloside may promote tumour progression and aggressiveness. 
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Chapter 5: Celecoxib promotes degranulation of CD8+ T 
cells in HPV-induced lesions of transgenic mice2 
  
  
                                                          
2
 The contents of this chapter were adapted from: 
 
- Santos C., Neto T., Ferrerinha P., Sousa H., Ribeiro J., Bastos M.M.S.M., Oliveira P.A., 
Medeiros R., Vilanova M., Gil da Costa R.M. (2015) Celecoxib promotes degranulation of CD8+ T 
cells in HPV-induced lesions of transgenic mice. Submitted to the journal Antiviral Research with 
the number AVR-D-16-00002. 
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Introduction 
 Human papillomavirus (HPV) has been described as an etiologic factor of several 
diseases, such as cervical and other anogenital cancers, and a subset of HPV-positive 
head and neck cancers [4, 6, 141, 142]. Oropharyngeal cancers have lately drawn 
considerable attention, given their growing incidence [152]. In order for a HPV-associated 
neoplasm to develop, a persistent infection by an oncogenic HPV type (mostly types 16 
and 18) is mandatory [3]. Only in a minority of cases, in which the immune system fails to 
eradicate the virus, will the infection progress to cancer [2]. 
 Cytotoxic T lymphocytes (CTL), differentiated from CD8+ T cells, play an important 
role in the complex immune response which accompanies HPV-induced carcinogenesis 
[11, 148]. CD8+ T cells are recruited to the lesions microenvironment by chemokines 
released by stromal and/or innate immune cells on site [149]. In the presence of activator 
stimuli, differentiated CTL can specifically target virus-infected and tumour cells, which are 
eliminated either through the release of lytic granules, engagement of death receptors 
(e.g. FAS-FASL or TRAIL) or following interferon-γ-dependent mechanisms [116-118]. In 
particular, CTL are critical to control cervical lesions and were recently demonstrated to 
drive the immune response in patients following the administration of an experimental 
therapeutic vaccine [171]. Recent studies have also shown the number of CD8+ T cells to 
be an important independent prognostic marker in HPV-positive head and neck cancer 
patients, while high CD8+ T cell levels correlate with a better prognosis, enhancing overall 
survival as well as progression-free survival [155, 172, 173]. Understanding and 
enhancing CTL function in patients with HPV-induced malignancies seems, therefore, a 
priority for cancer therapy.  
It has recently been suggested that cyclooxygenase-2 (COX-2) and its product 
prostaglandin E2 down-regulate the function of activated CD8+ T cells and induce their 
senescence [174]. This effect may explain how the abrogation of COX-2 signalling 
reduces tumour growth in mouse models of glioma [175] and mammary cancer [176]. In 
light of these findings, it is tempting to study whether CD8+ T cells present in HPV-induced 
lesions are affected by COX-2 inhibition.  
In this study, the aim was to examine the effect of a selective COX-2 inhibitor, 
celecoxib, on the infiltration and activation of CD8+ T lymphocytes in HPV-induced lesions. 
For this purpose, chest skin lesions of K14-HPV16 transgenic mice were employed [73]. 
These mice have been designed to target the expression of HPV16 oncogenes to skin 
and keratinized mucosal keratinocytes. The multi-stage disease progression in these mice 
greatly resembles HPV-associated disease in cancer patients, both morphologically and 
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molecularly [76], making K14-HPV16 mice a particularly useful model for HPV research. 
   
Material & Methods 
Animals 
 Generation of K14/HPV16 mice on a FVB/n background has been previously 
reported [73]. K14-HPV16 transgenic mice were kindly donated by Drs. Jeffrey Arbeit and 
Douglas Hanahan (University of California) through the USA National Cancer Institute 
Mouse Repository. The animal experiments were approved by the Universidade de Trás-
os-Montes e Alto Douro Ethics Committee (10/2013) and the Portuguese General 
Veterinary Directorate (approval no. 0421/000/000/2014). Animals were maintained and 
bred according to Portuguese (Decreto-Lei 113, August 7th) and European (EU Directive 
2010/63/EU) legislation, under controlled conditions of temperature (23 ± 2 ºC), light-dark 
cycle (12h light/12h dark) and relative humidity (50 ± 10 %), using corncob bedding. Food 
and water were provided ad libitum. 
 
Mice genotyping 
Animals were genotyped at weaning, using tail tip samples as described previously 
[113, 114]. Briefly, nucleic acids were extracted and DNA quality and purity were 
assessed. HPV16-E6 and -E2 genes were amplified to confirm the presence of HPV DNA 
and a fragment of mouse β-globin was also amplified as endogenous control. Lengths of 
the amplicons were confirmed by agarose gel electrophoresis. Only hemizygous females 
were used for the transgenic mouse groups in the experiment. 
 
Experimental Design 
 Fifty-four 18 to 20 weeks-old female mice were divided into four experimental 
groups, according to their genotype and taking into consideration that HPV transgenes 
and celecoxib (CXB) administration could induce some mortality: group 1 (HPV16-/- 
untreated animals, n = 12), group 2 (HPV16+/- untreated animals, n = 12), group 3 
(HPV16-/- CXB-treated animals, n = 15) and group 4 (HPV16+/- CXB-treated animals, n = 
15).  All surviving mice were humanely euthanized at 24-26 weeks of age by 
intraperitoneal pentobarbital overdose, followed by exsanguination by cardiac puncture. 
Chest skin samples (approximately 4 cm2) were collected for flow cytometry analysis and 
matched skin samples were collected for histological analysis. 
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Celecoxib administration 
Celecoxib (Pfizer, New York, NY) was dissolved in drinking water at a 
concentration of 0.5 mg/ml, estimating an average daily water intake of 5.0ml per mouse, 
and a dose of 46.7 mg/kg/day and 2.5 mg/animal/day in an average mouse weighting 30 
g. This is a well-tolerated moderate dose, as shown in previous assays [177]. However, 
K14-HPV16 animals dramatically increased their water intake when CXB was added 
(possibly due to the highly palatable lactose present in the vehicle) reaching up to 15 ml 
per animal. The CXB concentration was thus reduced from the start of the third week 
onwards down to 0.2 mg/ml, resulting in a decrease in consumption and an effective dose 
of 93 mg/kg/day and 2.8 mg/animal/day. The average dose during the overall 
experimental period was thus 124 mg/kg/day and 3.72 mg/animal/day. 
 
Histological Analysis  
 Skin samples were fixated in 10% neutral buffered formalin for 48 hours. Samples 
were dehydrated through graded alcohols and xylene and paraffin embedded in an 
automatic STP 120 processor (Micron, Boise, ID). 2 µm-thick sections were stained with 
haematoxylin-eosin (H&E) for histological evaluation on light microscopy. Skin samples 
were classified as normal skin, epidermal hyperplasia and epidermal dysplasia. 
 
Preparation of Single-Cell Suspensions 
 Chest skin samples were cut into small pieces after excessive blood vessels and 
fat tissue removal. Skin fragments were incubated for 2 hours with 125 U/ml type I 
collagenase (Gibco, Life Technologies, Paisley, UK) in RPMI-1640 medium 
complemented with 1% glutamine, 1% penicillin-streptomycin-amphotericin B, 1% HEPES 
buffer (all from Sigma, St. Louis, MO) and 10% foetal bovine serum (BioWest, Nuaillé, 
France) at 37 ºC and 150 rpm in a 3031 orbital incubator (GFL, Burgwedel, Germany). 
Subsequently, the resulting cell suspension was filtered and centrifuged at 300  for 10 
min at 4 ºC. Cells were ressuspended in phosphate buffered saline containing 1% bovine 
serum albumin and 20 mM sodium azide followed by flow cytometry analysis. 
 
Immunophenotyping 
Following cell isolation, the surface phenotype of the collected cells was assessed 
by flow cytometry using specific monoclonal antibodies (mAb). Cells were incubated with 
anti-mouse CD16/CD32 mAb for FcγR blocking, to prevent non-specific antibody binding. 
Next, cells were incubated with anti-CD8 mAb phycoerythrin-cychrome 5-conjugate (clone 
53-6.7, BD Biosciences, San Diego, CA) and anti-CD107a (LAMP1) mAb phycoerythrin-
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conjugate (clone eBio1d4b, eBioscience, San Diego, CA). Following extracellular staining, 
the cells were washed, fixed in 2% formaldehyde and washed with phosphate buffered 
saline containing 1% bovine serum albumin and 20 mM sodium azide. Antibody-labelled 
cells were analysed in an EPICS XL flow cytometer using the EXPO32ADC software 
(Beckman Coulter, Miami, FL). The assembled data files were analysed using the FlowJo 
software v10.0.7 (FLOWJO, LLC, Ashland, OR). 
 
Statistical Analysis 
Statistical analyses were performed using the GraphPad software (version 6.0, 
GraphPad Software, Inc. La Jolla, CA). In column and dot graphs each point represents 
individual mice, while bars represent the mean for the respective group. Statistical 
analysis between group pairs was done using the Mann-Whitney test. 
 
 
Results 
General findings 
All K14-HPV16 mice showed typical cutaneous changes, including diffuse 
hyperkeratosis and erythema. Celecoxib-treated HPV+/- mice (group 4) showed significant 
mortality: 10 out of 15 mice (66.7%) succumbed before the end of the study. All mice in 
groups 1, 2 and 3 survived until the end of the study. 
 
 Histological analysis 
 Histological analysis of skin samples (Table 2) showed that all WT mice, groups 1 
and 3, presented normal skin histology (Fig. 9a). In groups 2 and 4 (untreated and CXB-
treated HPV+/- mice, respectively), the totality of mice showed simple to papillary, diffuse, 
variably severe epidermal hyperplasia extending to the follicular infundibula and 
papillomatosis with orthokeratotic hyperkeratosis (Fig. 9b). Additionally, 2 animals (16.7%) 
from group 2 presented multifocal epidermal dysplastic foci with parakeratotic 
hyperkeratosis within the hyperplastic background (Fig. 9c). There were signs of mild 
inflammation, with a small amount of macrophages, mast cells and lymphocytes in the 
superficial dermis. Dysplastic foci were associated with increased numbers of leukocytes 
infiltrating the dermo-epidermic junction and with intense angiogenesis. 
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Table 2: Histological classification of HPV16-induced skin lesions from 24-26 weeks-old female mice. Celecoxib – 
CXB. 
Group 
Cutaneous lesions 
Incidence (%) 
 Normal skin Epidermal hyperplasia Epidermal dysplasia 
1 (HPV-/-, n = 12) 12/12 (100%) 0/0 (0%) 0/0 (0%) 
2 (HPV+/-, n = 12) 0/0 (0%) 12/12 (100%) 2/12 (16.7%) 
3 (HPV-/- + CXB, n = 15) 15/15 (100%) 0/0 (0%) 0/0 (0%) 
4 (HPV+/-+ CXB, n = 5) 0/0 (0%) 5/5 (100%) 0/0 (0%) 
 
 
Fig. 9: Histopathological changes induced by HPV16 oncogenes in FVB/n mice, H&E. a – WT animal; Normal skin 
histology, 100 . b – CXB-treated HPV16+/- animal; Epidermal hyperplasia extending to the follicular infundibulum 
and isthmus, 100 . c – Untreated HPV16+/- mouse; Epidermal dysplasia, 200 . Note marked parakeratotic 
hyperkeratosis, loss of cell polarity, enhanced anisokaryosis and mitotic activity. The dermal-epidermal junction is 
obscured by severe inflammatory cell infiltration. 
 
CTL infiltration and activation in celecoxib-treated mice 
 With the purpose to study CD8+ T cell infiltration in HPV-induced lesions, lymphoid 
cells from mice chest skin tissue were isolated and a flow cytometry analysis of the 
recovered cells was performed (Fig. 10a). Skin samples from untreated HPV+/- mice 
showed a significantly higher percentage of CD8+ T cells compared with untreated WT 
animals (P  0.01) (Fig. 10b). Also, although statistical significance was not achieved, 
CXB-treated WT mice showed decreased CD8+ T cell infiltration when compared to CXB-
treated HPV+/- animals and the same was observed between samples from WT mice 
treated with CXB (group 3) and untreated WT animals (group 1) (Fig. 10b). Moreover, 
HPV+/- mice treated with CXB (group 4) showed less CD8+ T lymphocytes compared with 
untreated transgenic animals (group 2) (P  0.01) (Fig. 10b).   
 Next, the objective was to study whether the CD8+ T lymphocytes found in mouse 
skin samples showed signs of cytotoxic activity (Fig. 10a). Thus, expression of CD107a 
(LAMP1) at the cell surface was assessed by flow cytometry. CD107a reaches the surface 
of CTL when lytic granules are released, exposing their membrane proteins during 
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exocytosis [144]. Thus, this lysosome-associated membrane protein is frequently used as 
an immunological marker of CTL degranulation [145]. Fig. 10c shows a significantly higher 
percentage of CD8+CD107a+ cells in samples from HPV+/- mice treated with CXB (group 
4) when compared with untreated HPV+/- (group 2) (P  0.01). 
 
 
Fig. 10: Percentage of CD8+ and CD8+CD107a+ T cells within total lymphoid-gated cells obtained from chest skin 
samples from WT and K14-HPV16 transgenic mice. a – Representative analysis of the gating strategy employed. 
Numbers within graphs correspond to the percentage of the gated population. b – Percentages of CD8+ T cells and 
c – percentages of CD8+CD107a+ T cells in gated CD8+ T cells were determined by flow cytometry after skin tissue 
collection and digestion with collagenase. Chest skin samples were collected from WT and HPV+/- mice (Groups 1 
and 2, respectively) and CXB-treated (CXB) WT and HPV+/- mice (Groups 3 and 4, respectively) at 24-26 weeks of 
age. Group 1, n = 5; Group 2, n = 5; Group 3, n = 5; Group 4, n = 5. Each dot represents an individual animal. Bars 
represent the mean value in each group. ** P  0.01. 
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Discussion 
 The development of HPV-associated malignancies depends on a persistent HPV 
infection. Ultimately, the ability of the immune system to eliminate the virus is the key 
element to decide whether a HPV infection is cleared or evolves to cancer [2]. HPV 
presents well-known mechanisms to evade host immunity and delay its elimination, thus 
facilitating viral persistence [154]. When the virus is detected, an innate immune response 
occurs, and leads to the development of an adaptive immune response. A fundamental 
part of this adaptive response is cell-mediated immunity, characterized by the activity of a 
vast number of CD8+ and CD4+ T lymphocytes [39]. In fact, infiltration by these cells in 
HPV-associated lesions has already been shown to lead to regression [148, 178]. CTL 
infiltration drives the response induced by an experimental therapeutic vaccine in patients 
with cervical intraepithelial lesions [171] and correlates with a better prognosis in patients 
with HPV-positive head and neck cancer [155, 172, 173]. 
Chronic inflammation is a key feature associated with carcinogenesis, namely in 
the case of HPV infection [8]. COX-2 is an enzyme with an imperative role in the 
metabolism of arachidonic acid, which leads to the production of prostaglandins, which in 
turn promote inflammation [129]. In fact, COX-2 is over-expressed in several 
malignancies, including cervical cancer [130-134]. As inflammation is known to contribute 
for cancer progression [8], COX-2 inhibition is expected to result in tumour growth 
inhibition whilst reducing inflammation. Some non-steroidal anti-inflammatory drugs, like 
aspirin and ibuprofen, have already shown promising results as anti-tumour therapy in 
both patients and pre-clinical animal models [179-182]. However, these drugs have very 
low specificity. Selective COX-2 inhibitors such as CXB and rofecoxib have already been 
used to prevent the development of colorectal adenomas [183, 184]. Furthermore, this 
COX-2 inhibitor has been showing promising results in a tumour model of human colon 
cancer when combined with chemotherapeutic drugs [185]. 
In this study, the effect of the selective COX-2 inhibitor CXB over the trafficking 
and activation of CD8+ T lymphocytes was examined in the K14-HPV16 mouse model, a 
proper model to study HPV-induced carcinogenesis due to its great similarities with the 
human clinical disease [76]. High mortality was observed among CXB-treated animals, 
presumably due to CXB-related toxicity.  
The results presented herein show that CXB reduces the number of tumour-
infiltrating CD8+ T cells when compared with untreated mice. Still, despite the decrease in 
cell numbers, CXB-treated mice have a higher percentage of activated and degranulating 
CTL compared with untreated animals. These findings suggest that CXB reduces the 
number of tumour-infiltrating CD8+ T cells while enhancing their effector functions. These 
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data are in agreement with a previous study using glioma-bearing mice where COX2-/- 
mice had increasing percentages of tumour-infiltrating CD8+CD107a+ lymphocytes [175]. 
This may be explained by another study reporting that COX-2 activity leads to CD8+ T cell 
senescence and this trajectory may be opposed by COX-2 inhibition, as shown by 
increased levels of CD28 and interleukin-2 in CD8+ T cells [174]. 
Furthermore, hyperplastic epidermal lesions were evident in all surviving 
transgenic mice, whilst all WT animals presented normal skin histology, as expected. 
Multifocal dysplastic epidermal lesions were restricted to untreated HPV+/- animals. These 
findings suggest that CXB blocked tumour progression at the hyperplastic stage, but the 
small number of dysplastic lesions observed does not allow for any definitive conclusions. 
In fact, COX-2 inhibition boosted the efficacy of a DNA vaccine expressing the HPV E7 
oncogene, by enhancing tumour-infiltrating CD8+ T cells and slowing tumour growth [186]. 
However, this study was performed in mice bearing allografted TC1 lung cells 
immortalized by the HPV16 E6 and E7 oncogenes and transformed by the c-Ha-ras 
oncogene. Comparisons between this model and K14-HPV16 mice are limited, because 
allografts do not reproduce HPV-associated multi-step carcinogenesis, being directly 
implanted in the subcutis with a fully malignant phenotype. Also, keratinocytes and not 
lung cells are the targets for papillomavirus infection. 
It remains unclear whether CTL are activated at regional lymph nodes or at the 
lesion location and this would be an interesting point to address in the future. The results 
presented herein suggest that CXB induces augmented CTL degranulation in HPV-
induced lesions, possibly contributing to prevent malignant progression in this animal 
model.  
 
Conclusion 
 The present data confirm the potential of CXB to enhance degranulation by 
tumour-infiltrating CD8+ T lymphocytes. Moreover, the effect of CXB seems to be more 
complex than previously thought, as it also reduced the overall number of tumour-
infiltrating CD8+ T cells. Future studies addressing the impact of COX-2 inhibitors on the 
prognosis of patients bearing HPV-induced lesions should take into account both the 
number of infiltrating CD8+ T cells and their activation status. 
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Chapter 6: General Discussion and Conclusions 
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 HPV-associated malignancies are a genuine health problem worldwide, with 
emphasis on the increase in the number of HPV-associated oropharyngeal carcinomas 
[152]. Prophylactic vaccination remains the most effective method to control HPV 
infections. Currently, there are two effective commercialized vaccines: Cervarix™ 
(GlaxoSmithKline Biologicals, Rixensart, Belgium), a bivalent HPV16/18 vaccine; and 
Gardasil™ (Merck Vaccines, West Point, PA), a quadrivalent HPV6/11/16/18 vaccine. 
Both are HPV L1 virus-like particles (VLP) vaccines and they act by boosting the 
production of neutralising antibodies directed against the L1 capsid protein [187]. Despite 
their effectiveness, these vaccines present a few limitations, as the virus-type restriction. 
The first is restricted to two HPV types (bivalent) and the second is restricted to four types 
(quadrivalent). Looking to increase type-specific protection, Merck managed to create the 
nonavalent HPV L1 VLP vaccine by adding the VLPs from five oncogenic HPV types (31, 
33, 45, 52 and 58) in addition to the four types used in the quadrivalent vaccine. This 
resulted in a 20% increase in protection, in addition to the 70% obtained from the 
quadrivalent vaccine, in a total of approximately 90% protection against cervival cancer 
[188]. However, despite these advances in disease prevention, an effective therapeutic 
vaccine against HPV-induced malignancies remains absent. 
 In order to develop a therapeutic strategy, it is necessary to gather a large amount 
of information on the features of disease progression as well as of the events occurring in 
the lesions microenvironment. It is accepted that the carcinogenesis process induced by a 
HPV infection is marked by the existence of a prominent immune response [11, 18]. Thus, 
a great deal of cellular populations and chemical factors are present and play a specific 
role in carcinogenesis, either promoting or impairing it. At the end, it should be the 
balance between all pro- and anti-tumour stimuli that will decide whether the viral infection 
is cleared or is allowed to progress towards malignancy. Therefore, a therapeutic vaccine 
could possible enhance the action of anti-tumour effectors and/or inhibit the function of 
known pro-tumour mediators. 
 Cytotoxic CD8+ T lymphocytes, for instance, are the main cells associated with the 
elimination of virus-infected and transformed cells. These cells are part of the adaptive 
immune response and depend on antigen presentation by MHC I molecules and other co-
stimulatory signals to become activated and exert their functions [116, 117]. However, 
during the course of HPV infection, expression of MHC I molecules is usually down-
regulated. This is one of the most common immune evasion mechanisms employed by 
the HPV E5 oncoprotein [154]. Infiltration of CD8+ T cells in HPV-positive lesions has 
already been associated with better prognosis when compared with HPV-negative ones 
[155, 172, 173, 189]. Thus, boosting the activity of CD8+ T lymphocytes seems a possible 
therapeutic strategy to eliminate HPV-associated lesions. Still, the HPV immune evasion 
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mechanisms, namely MHC I molecules down-regulation, should by some means be 
reversed in order to increase the efficacy of the CTL boosting. 
 Nevertheless, modulation of a lesion microenvironment (particularly, the CD8+ T 
cells) can be accomplished by a great variety of substances such as toxins or medical 
drugs. For instance, humans can become easily exposed to bracken (Pteridium spp.) – 
and more importantly to its major toxin, ptaquiloside – through bovine and ovine milk and 
meat consumption or ingestion of contaminated water [161-164]. Ptaquiloside can cause 
several immunosuppressive events such as neutropenia, diminished NK cell cytotoxicity, 
reduced expansion of antigen-specific T lymphocytes and B-cell lymphoproliferative 
malignancy [125-128]. However, its effect over CTL or HPV-induced lesions was not 
addressed until this moment. In turn, the effect of the selective COX-2 inhibitor celecoxib 
over CD8+ T cells has already been examined in a number of studies albeit not in the 
context of HPV-induced lesions and with inconsistent results [136-140]. This anti-
inflammatory drug appears as a possible therapeutic drug against inflammation-
associated cancers where COX-2 is over-expressed. 
 The K14-HPV16 transgenic mouse model stands out as an excellent replica to 
study HPV-associated carcinogenesis. Its greatest advantage is the targeted expression 
of the entire HPV early region genes to skin and keratinized mucosal keratinocytes by the 
cytokeratin-14 promotor. This model expresses the virus proteins in the same cell types 
that are infected by HPV in human patients, therefore supporting the use of this model. 
Furthermore, the microscopic morphologic similarities between this mouse and the human 
disease also validate its appliance in HPV-induced carcinogenesis research [76]. 
Therefore, the K14-HPV16 mice can be employed in the study of the immune response 
against HPV and, more precisely, in the disclosure of the infiltrating cells in the lesions 
microenvironment. In addition, this model is appropriate to study the immunomodulatory 
effects of multiple substances at the lesions microenvironment. Hence, in this work, these 
transgenic mice were utilized to analyse the infiltration and activity of CD8+ T cells in HPV-
induced lesions at different ages and after the treatment with two distinct 
immunomodulatory agents. 
 The results presented herein suggest that CD8+ T lymphocytes heavily infiltrate 
HPV-induced lesions. These cells show signs of cytotoxic activity and the number of 
degranulating CTL increases in response to more aggressive lesions. However, CTL 
infiltration and degranulation were not sufficient to induce lesion regression. This may be 
related to the model now employed, in which all keratinocytes express the HPV 
oncogenes. In these conditions, even if many neoplastic keratinocytes are cleared by the 
immune response, there are no normal cells to replace them, but only an endless 
population of transformed cells that will sustain tumour progression. 
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Furthermore, the CD8+ T cell response can be modulated. Ptaquiloside impaired 
the cytotoxic activity of these cells and diminished the differentiation of memory CTL. 
Apparently, ptaquiloside promoted the development of more aggressive lesions, although 
this correlation could not be statistically confirmed.  This is likely to constitute another 
mechanism through which ptaquiloside contributes to the persistence and the malignant 
transformation of viral lesions. 
In contrary, celecoxib significantly enhanced the release of lytic granules by CTL, 
even though greatly reducing the number of infiltrating lymphocytes. However, increased 
cytotoxicity was not perceptibly associated with lesion regression, which may be due to 
the model limitations, as outlined above. Nonetheless, the focus of this work was the 
characterization of the CD8+ T cell infiltrate. Thus, additional studies are required to 
understand why CTL activity is not sufficient to induce the regression of HPV-associated 
lesions. 
 In the near future it will be worth exploring which other immune cellular populations 
may also infiltrate HPV-induced lesions and what soluble mediators they could be 
producing. This knowledge should provide a better characterization on the pro- and anti-
tumour stimuli in the lesion microenvironment, therefore helping to decide which cells 
should be boosted and which should be inhibited in order to attain regression. In 
conclusion, this work once more recognizes the value of the K14-HPV16 transgenic 
mouse model for HPV-induced carcinogenesis research and it should also be a very good 
model for the testing of new therapeutic strategies. Finally, the results presented here are 
encouraging in regard to the search for lesion regression, as they show high infiltration 
and activity of the most common anti-tumour immune effector cells. 
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